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Stroke is the leading cause of long-
term disability and a major burden 
on health-care resources worldwide. 
Embolism of cardiac origin accounts 
for 15–30% of ischemic strokes. Most 
cardiac thrombi originate from the 
left atrial appendage. An enlarged left 
atrial appendage may predispose the 
individual to blood coagulation and 
increase the risk of embolic events. 
By using computed tomography the 
left atrial appendage was found to be 
enlarged in more than half of patients 
with cryptogenic stroke.
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ABSTRACT
Stroke is the leading cause of long-term disability and a major burden on health-care resources 
worldwide. Stroke is responsible for 10% of all deaths being the second most common cause of 
mortality. Embolisms in the brain can be of either arterial or cardiac origin. Atrial fibrillation is by 
far the most common cause of cardioembolic stroke. Embolisms from cardiac origins account for 
15–30% of ischemic strokes. Strokes due to cardioembolism are generally severe and they have a 
high frequency of early and long-term recurrence and mortality. Ischemic strokes, which have no 
well-defined etiology, are designated as cryptogenic and they account for 30–40% of all ischemic 
strokes. It has been postulated that cardiac embolism may also constitute a major mechanism for 
cryptogenic stroke.
Most cardiac thrombi originate from the left atrial appendage. An enlarged left atrial appendage 
may predispose the individual to blood coagulation due to slow flow velocity. Previous studies 
have revealed an enlarged left atrial appendage in stroke patients with atrial fibrillation. Moreover, 
an enlarged left atrium and left atrial appendage could indicate a propensity for paroxysmal atrial 
fibrillation, regardless of sinus rhythm at the time of the ischemic episode.
All patients with suspected stroke undergo computed tomography for the exclusion of intrac-
ranial hemorrhage. It would be ideal to assess the risk of recurrent cardioembolic stroke during a 
simultaneous imaging session. It was hypothesized that the anatomical features of the left atrial 
appendage could be assessed in patients with stroke with computed tomography and that anatomy 
may be altered in patients with cryptogenic stroke compared in comparison to the situation in nor-
mal subjects. Another goal was to assess the multifactorial etiology of left atrial appendage enlarge-
ment in patients with suspected cardiogenic stroke without atrial fibrillation. 
It was found that left atrial appendage volume measurements were reproducible irrespective of 
image quality or scanner generations. The extent of left atrial appendage enlargement was poorly 
linked with known causative stroke risk factors and other imaging measurements, implying that 
this phenomenon has a relatively independent pathogenic mechanism for cardioembolic stroke. 
The left atrial appendage was enlarged in more than half of patients with cryptogenic stroke. Based 
on measurements conducted in the control population, a mid-diastolic left atrial appendage vol-
ume larger than 5.6 mL/m2 was indicative of left atrial appendage enlargement. 
Currently, further examination for asymptomatic atrial fibrillation of patients with an enlarged 
left atrial appendage in cardiac computed tomography may be recommended, since atrial fibrilla-
tion as an etiology for stroke may significantly affect the treatment selected for these patients.
National Library of Medical Classifications: Brain ischemia. Stroke [WL 356]; Heart [WG 201]; Heart Atria [WG 
201-202]; Intracranial Embolism  [WL 355], Tomography, X-Ray Computed [WN 206] 
Medical Subject Headings: Stroke [C14.907.253.855]; Atrial Appendage [A07.541.358.100]; Heart Atria 
[A07.541.358]; Tomography, X-Ray Computed [E01.370.350.350.810]
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TIIVISTELMÄ
Aivoverenkiertohäiriö on merkittävin vammaisuuden aiheuttaja aikuisväestössä ja se kuluttaa 
terveydenhuollon voimavaroja enemmän kuin mikään muu sairaus. Kymmenes kaikista kuolemis-
ta johtuu aivoverenkiertohäiriöistä niiden ollessa maailman toiseksi yleisin kuolinsyy. Aivoveri-
suonia tukkiva verihyytymä voi olla peräisin suonen seinämästä tai sydämestä. Kaikista hapen-
puutteeseen johtavista eli iskeemisistä aivoverenkiertohäiriöistä 15–30 % johtuu sydänperäisistä 
syistä. Eteisvärinä on yleisin syy sydämen sisäisen verihyytymän muodostumiseen. Sydänperäiset 
aivoverenkiertohäiriöt johtavat muita aivoverenkiertohäiriöitä useammin vaikea-asteisiin oireisiin 
tai kuolemaan. Aina aivoverenkiertohäiriön syytä ei kyetä tunnistamaan. Syntymekanismiltaan 
selvittämättömiksi eli kryptogeenisiksi jääneitä aivoverenkiertohäiriöitä on noin 30–40 % kaikista 
iskeemisistä aivoverenkierohäiriöistä. Sydänperäisten syiden on esitetty selittävän suurimman 
osan kryptogeenisistä aivoverenkiertohäiriöistä.
Suurin osa kaikista sydänperäisistä verihyytymistä muodostuu vasemmassa eteiskorvakkeessa. 
Suurentunut eteiskorvake voi hidastaa verenvirtausta ja altistaa yksilön tavallista suuremmalle 
verihyytymämuodostumariskille.  Eteiskorvakkeen on havaittu aiemmissa tutkimuksissa suuren-
tuneen eteisvärinäpotilailla. Suurentuneen eteiskorvakkeen on arveltu kertovan eteisvärinätaipu-
muksesta, vaikka potilaalla tutkimushetkellä olisi normaali sinussolmukeperäinen rytmi.
Kaikki potilaat, joilla epäillään aivoverenkiertohäiriötä, kuvataan tietokonetomografialla 
aivoverenvuodon poissulkemiseksi. Iskeemisen aivoverenkiertohäiriön syytä voisi samalla selvit-
tää arvioimalla sydämen vasemman eteiskorvakkeen anatomiaa. Tutkimuksesta voisivat hyötyä 
potilaat, joille ei ole kyetty löytämään muuta syytä aivoverenkiertohäiriölle. Tämän väitöskirja-
tutkimuksen yhtenä tavoitteena oli kartoittaa syitä eteiskorvakkeen suurenemiselle iskeemisessä 
aivoverenkiertohäiriöpotilasaineistoissa, jossa ei ole todettu eteisvärinää.
Väitöskirjatyössä havaittiin, että tietokonetomografialla tehdyt sydämen vasemman eteiskor-
vakkeen tilavuusmääritykset olivat toistettavia kuvalaadusta ja kuvantamislaitteen tarkkuudesta 
riippumatta. Vasemman eteiskorvakkeen suureneminen selittyi heikosti muilla, aiemmin tunne-
tuilla aivoverenkiertohäiriön riskitekijöillä tai tavanomaisesti sydämen kuvantamistutkimuksissa 
otetuilla mittauksilla. Vasemman eteiskorvakkeen tilavuuden suureneminen voi olla itsenäinen 
riskitekijä sydänperäiselle aivoverenkiertohäiriölle. Väitöskirjatutkimuksessa havaittiin, että vasen 
eteiskorvake oli merkittävästi suurentunut yli puolella kaikista kryptogeenisistä aivoverenkierto-
häiriöpotilaista. Verrokkipotilasaineiston avulla vasemman eteiskorvakkeen raja-arvoksi määritet-
tiin 5,6 ml/m2. Mikäli akuutista aivoverenkiertohäiriöstä kärsivän potilaan eteiskorvake on suuren-
tunut, voisi jatkossa olla hyödyllistä kohdentaa tavallista laajempia rytminseurantatutkimuksia 
juuri tähän potilasjoukkoon oikean hoitomuodon tarjoamiseksi ja vakavien uusintakohtausten 
välttämiseksi.
Yleinen Suomalainen Asiasanasto: sydän, radiologia, tietokonetomografia, aivoverenkiertohäiriöt, ohimenevä 
aivoverenkiertohäiriö, aivoinfarkti, tilavuus, eteisvärinä, sydän- ja verisuonitaudit, riskitekijät, anatomia. 
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Die Wissenschaft kennt nur ein Gebot: den wissenschaftlichen Beitrag.
Bertolt Brecht – “Leben des Galilei”
Science knows only one commandment: contribute to science.
Bertolt Brecht – in his play “Life of Galileo”
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First documents concerning stroke originate from the 2nd millennium BCE and come from ancient 
Mesopotamia and Persia (1, 2). Hippocrates (460 to 370 BCE) was the first individual to describe the 
relationship between a sudden paralysis on the opposite side to a cranial trauma (3). The first writ-
ten description of transient ischemic attack (TIA) derives from hippocratian aphorism (4).
In 1658, a Swiss physician Johann Jakob Wepfer described a carotid thrombosis in a patient with 
a completely occluded right internal carotid artery (5). His opus magnum Apoplexia included the 
examples of completed stroke, progressing stroke, TIA, and reversible ischemic neurological deficit 
(6). In 1856, Rudolf Virchow first described the mechanism of thromboembolism as a major factor 
in ischemic stroke (7). The heart was established as an important source for the embolus formation 
by the English physician Sir William Richard Gowers, in 1875. Already then, left atrial appendage 
(LAA) was suspected to be the main site of thrombus formation (8). 
Nowadays LAA is believed to have an increasingly significant role in the cardiac anatomy (9, 
10). It is now recognized that LAA is a structure with important pathological associations (11). Ap-
proximately 90% of intracardiac thrombi originate from LAA (12). A hrombus has a predilection 
to form within the LAA in patients with atrial fibrillation (AF), but in many cases AF cannot be 
identified in patients with suspected cardioembolism (13, 14). There are also other factors associ-
ated with thrombus formation (15-17). Since thrombi in LAA represent such an important source of 
emboli which can be treated, their accurate detection could markedly improve patient care (18-20). 
There are several ways to evaluate LAA size, blood flow patterns and content but transesophageal 
echocardiography (TEE) is the clinical gold standard (13, 21, 22). However, TEE requires special 
skills for reliable performance and interpretation and its accuracy for anatomical evaluation is 
somewhat limited. Additionally, it is a relatively invasive test. (21, 23, 24)
This doctoral thesis focuses on whether the assessment of LAA anatomy could be combined 
with conventional computed tomography (CT) imaging of stroke patients. Furthermore, second-
ary topic of this thesis is whether there would be a difference in LAA volumes between acute 
cryptogenic stroke patients and age- and gender-matched healthy control subjects. It also aimed to 
study which factors associated with LAA volume increase and it has attempted to determine the 
reproducibility of LAA and LA volume measurements.
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2.1 DEFINITIONS AND MANIFESTATIONS OF ISCHEMIC STROKE
The name stroke refers to a neurological deficiency due to a disturbance in the blood supply to the 
brain, usually because of ischemia (87%) originating from a blockage of an artery (thrombosis, arte-
rial embolism), or an intracerebral or subarachnoid hemorrhage (13%) (25, 26). An acute brain CT 
scan is performed to distinguish ischemic strokes/TIAs from the hemorrhage form (27-29). If the 
neurological symptoms continue for over 24 hours, a person will be diagnosed as having a stroke; 
otherwise, a focal neurological deficit lasting less than 24 hours is defined as a transient ischemic 
attack (TIA) (30). In recent years, the distinction between ischemic stroke and TIA has become less 
important since the same preventive approaches may be applied to the both groups (31). Despite 
the differences in prognosis depending on the cause and severity of the symptoms, both stroke and 
TIA share the same pathogenetic mechanisms (32).
With the more widespread use of modern brain imaging, many patients with symptoms lasting 
less than 24 hours are known to exhibit a lesion in the cerebral parenchyma (33). The most recent 
definition of stroke for clinical trials has required either symptoms lasting over 24 hours or imaging 
of an acute clinically relevant brain lesion in patients with rapidly vanishing symptoms (34). This 
has meant that the definition of TIA is now more like a brief episode of neurological dysfunction 
caused by a focal disturbance of brain or retinal ischemia, with clinical symptoms typically lasting 
less than 1 hour, and without evidence of infarction (35-37). The etiological assessment of stroke/
TIA is important, while 90-day risk of stroke recurrence is reported to be as high as 10.5% with the 
stroke risk being greatest during the first week (38).
2.2 BURDEN OF THE DISEASE
Stroke ranks as the second most common cause of death and the third most common cause of 
disability-adjusted life-years in global terms in 2010. Stroke is responsible for 10% of deaths and 
about 4% of disability-adjusted life-years. (39) Although stroke mortality rates have decreased since 
the early 1990s’, the global burden of stroke in terms of the absolute number of people annually 
affected, stroke survivors, related deaths, and disability-adjusted life-years lost is increasing (40). 
Stroke exerts its greatest impact in the Third World (41). If these trends in stroke incidence, mortal-
ity, and disability-adjusted life-years continue, then by 2030 there will be almost 12 million deaths, 
70 million survivors, and more than 200 million disability-adjusted life-years lost globally due to 
stroke (42). Although the mean age of stroke patients is increasing in both the First and the Third 
World, the proportion of stroke victims younger than 65 years is 32% (43).
Differences in the prevalence, significance and control level of stroke risk factors as well as in the 
accessibility of health services account for much of the large geographical variations in stroke inci-
dence (44-46). The significantly greater prevalence of stroke in high-income than in low-income and 
middle-income countries is associated with an inverse association between prevalence of stroke 
and stroke mortality and disability-adjusted life-years lost (47). In conjunction with increased mor-
tality-to-incidence ratios in the Third World countries, it is has been posturated that the differences 
in the management of acute stroke are the most likely explanation of differences in stroke preva-
lence, i.e. poorer stroke management is associated with increased fatality and subsequently with a 
lower stroke prevalence (48, 49).
2.3 SUBTYPES OF ISCHEMIC STROKE
Forty years ago, brain CT in the stroke diagnostics was in its infancy (50).  Cerebral angiography 
was the major diagnostic tool in that era and Harvard Cooperative Stroke Registry (1978) was one 
of the few epidemiological stroke studies carried out using a CT-based diagnostic program (51). 
While only 3% of patients underwent CT, one half of these was diagnosed only by clinical symp-
toms (52). The purpose of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification 
4system was to imrove the categorization of stroke patients with the actual purpose of elucidating 
the potential efficacy of the anticoagulant drug danaparoid in the treatment of various types of 
ischemic strokes (53).  Even though the trial failed to reveal any efficacy for danaparoid, the TOAST 
classification system has been used extensively for other purposes, such as identifying new genetic 
markers and risk factors (54). The TOAST classification includes five etiological categories: 1) large-
artery atherosclerosis, 2) cardioembolism, 3) small-artery occlusion, 4) stroke of other determined 
etiology, and 5) stroke of undetermined etiology (cryptogenic). The classification of stroke is based 
on patients’ clinical status and on imaging and laboratory data collected by various diagnostic tests 
and imaging modalities (53). Other established classifications are Causative Classification System 
(CCS) and the Atherosclerosis Small Vessel Disease Cardiac Source Other Cause (ASCO) classifica-
tion, both of which provide similar distributions of underlying etiologies compared to TOAST (55, 
56).
2.3.1 Large-artery atherosclerosis
The diagnosis of stroke due to large-artery stenosis is based on stroke symptoms and cerebral 
imaging findings explained by either significant (>50%) stenosis or occlusion of a carotid or a ver-
tebral artery or a branch of cortical artery (57, 58). The clinical findings can include cerebral cortical 
impairment such as aphasia, neglect, restricted motor involvement or dysfuction of brain stem or 
cerebellum (59). Cortical, cerebellar, brain stem or subcortical hemispheric infarcts with a diameter 
greater than 1.5 cm on CT or magnetic resonance imaging (MRI) are considered to be of large-artery 
atherosclerotic origin (53, 60-62). TOAST criteria require the exclusion of the possibility of car-
diogenic embolism with proper laboratory tests including 24 hour ambulatory electrocardiogram 
(ECG) Holter and transesophageal echocardiography (63). Clinically significant carotid stenoses 
are defined as >50% lumenal narrowing (64).
2.3.2 Cardioembolism
A cerebral infarct where the embolism has arisen from the heart is called a cardiogenic stroke (53). 
Cardiogenic embolism is the cause of approximately 20% of ischemic strokes (65). Cardiac sources 
are divided into high-risk and medium-risk groups based on the evidence of their relative propen-
sities towards embolism (63, 66-72). The cardiac source for an embolus must be identified before 
one can make a diagnosis of cardioembolic stroke (73). Cortical, cerebellar, brain stem or subcorti-
cal hemispheric infarcts with a diameter greater than 1.5 cm on CT or MRI can be considered to be 
of a potentially cardioembolic origin (74, 75). The possibility of large-artery atherosclerosis must 
be excluded. Evidence of a previous TIA or stroke in more than one vascular territory or systemic 
embolism is support for the diagnosis of a cardioembolic origin of the symptoms (76, 77). The 
cardioembolic sources of stroke have been associated with both the youngest and the oldest stroke 
patient groups (78). It seems that the ischemic strokes occurring in patients with AF are recurrent 
and more severe than in patients in sinus rhythm (77). Up to 68.6% of these strokes have a hemor-
rhagic transformation (79). The clinical stratification of thromboembolic and bleeding risk and the 
consideration of comorbidities will determine the use of antithrombotic treatment (80-82).
Nontheless the diagnosis of a cardioembolic source of stroke is frequently uncertain and relies 
on the identification of a potential cardiac source of embolism (34). At present, there are some ma-
jor risk factors which have been identified i.e. AF (83), recent myocardial infarction (84), previous 
myocardial infarction (LV aneurysm) (85), primary or secondary cardiomyopathies (86-88), cardiac 
masses (such as intracardiac thrombus, intracardiac tumours, fibroelastoma or Marantic vegeta-
tions (89-92)), rheumatic valve disease (mitral stenosis) (93), aortic arch atheromatous plaques (94), 
endocarditis  (95) and mechanical valve prosthesis (96). Current knowledge also indicates, that 
there are minor or unclear risk sources i.e. mitral valve prolapse (97-100), mitral annulus calcifica-
tion (101), calcified aortic stenosis (102, 103), atrial septal aneurysm (104), patent foramen ovale 
(105-107) and Giant Lambl’s excrescences (108).
2.3.3 Small-artery occlusion 
Stroke patients with a normal cerebral CT/MRI examination or a relevant brain stem or subcortical 
hemispheric lesion with a diameter of less than 1.5 cm are labelled as having a small-artery occlu-
sion (109-111). These patients are demonstrated was having one of the traditional clinical lacunar 
5syndromes without any evidence of cerebral cortical dysfunction (112). Small-artery occlusion is 
supported by a previously diagnosis of diabetes or hypertension (113). Before the condition can 
be deemed to be a small-artery occlusion, one must exclude the possibility of cardioembolism and 
ipsilateral large artery atherosclerosis greater than 50% (114).
2.3.4 Acute stroke of other determined etiology
Stroke may be atributable to rare causes such as non-atherosclerotic vasculopathies, hypercoagu-
lable states, or hematologic disorders (115). The types of patients display both the clinical and 
imaging findings of an acute ischemic stroke (29). Stroke due to other determined etiology may 
vary in the terms of size and location. Diagnostic laboratory tests or imaging must identify the unu-
sual cause of the stroke symptoms. And as before, cardioembolism and large-artery atherosclerosis 
must be excluded. (116)
2.3.5 Stroke of undetermined etiology
Frequently, the cause of stroke cannot be determined with any degree of confidence. Some patients 
will have no obvious etiology despite undergoing an extensive evaluation. In others, no cause is 
found but the evaluation has been cursory. This category also includes those patients with two or 
more potential causes of stroke so that the physician is unable to make a final diagnosis. For exam-
ple, a patient with a medium-risk cardiac source of embolism who also has another possible cause 
of stroke identified would be classified as having a stroke of undetermined etiology. (53)
2.3.5.1 Cryptogenic stroke
The term cryptogenic stroke generally refers to a stroke with no specific cause after a comprehen-
sive evaluation for the most common causes and is therefore included into the category Stroke of 
Undetermined Etiology as described in the TOAST criteria (53). There are over 150 known causes 
for stroke (117).  
A classification of cardiac sources or major arterial atheroma will be assigned when a unique 
cardioembolic cause or cause related to atheroma of the major arteries has been identified. The 
classification of multiple sources will be assigned when several potential causes are identified in 
the same patient, and a classification of cryptogenic assigned when no cause is found. The defini-
tion of cryptogenic stroke therefore demands that there has been an extensive diagnostic imaging 
of the aorta and its thoracic carotid / vertebral artery branches. The exclusion of the cardiogenic 
origin of the stroke is based on echocardiography and 24 hour ECG Holter recording. Small artery 
atherosclerosis may be suspected when cerebral MRI/CT shows no signs in the brain stem or the 
subcortical cortical hemispheric lesion greater then 1.5 cm. Routine blood investigations including 
blood cell count must be completed with thorough prothrombotic tests i.e. plasma determinations 
of antiphospholipid antibodies and lupus anticoagulant, S and C protein deficiencies, and genetic 
analysis of the prothrombin gene mutation (PT G20210A) and the factor V Leiden mutation (FV 
G1691A) and Von Willebrand factor.  (118-123)
Cryptogenic stroke has been shown to account for 23% to 40% of patients and it is more frequent 
in younger patients (124-126). Concerns about cryptogenic stroke are relevant as there are reports 
of the relatively high risk of stroke recurrence (127). No special treatment is often recommended in 
patients with cryptogenic stroke, therefore an erroneous diagnosis places the patient at a real risk 
of future complications (128). Since recurrent strokes are mainly the same subtype as the preced-
ing index stroke, it is essential to facilitate the iidentification of therapies which would target the 
underlying cause of the index stroke (129). 
Cryptogenic strokes frequently have embolic features suggestive of a cardiogenic origin (130). 
Over half of cryptogenic strokes are predicted to be of cardioembolic origin, since patients with 
cryptogenic stroke have had more prior myocardial infarctions and more risk factors for AF as 
compared to stroke patients with stroke of predicted arterial etiology (131).  It has been shown that 
in over 24% of patients assumed to have a cryptogenic stroke/TIA, AF may be found if one uses 
long-term ECG registrations (132).The genetic architecture of cryptogenic stroke remains uncertain, 
although some rare coding variants may predispose the individual to the risk of ischemic stroke 
(115).
 
62.4 ANATOMY AND PHYSIOLOGY OF THE GREAT CIRCULATION  
Heart, enclosed in the pericardium, is located on the left side of the thoracic cavity (133). The heart 
contains four chambers, two superior atria and two inferior ventricles. The left atrial appendage is 
connected laterally to the atria (134). During the cardiac cycle, blood circulates from the receiving 
atria into discharging ventricles. Deoxygenated blood from the great circulation is led through the 
right side of the heart into the pulmonary arteries of minor circulation (135). Oxygenated blood 
drains into left atrium and from there back to the systemic circulation via the left ventricle (136).
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Figure 1. Changes in atrial and ventricular pressure and volume during the cardiac cycle associated with elec-
trocardiogram and phonocardiogram markers. Two complete cycles are illustrated. In the atrial pressure curve, 
the a-wave occurs during the contraction of the right atrium when the tissue squeezes out extra blood just be-
fore ventricular systole (early atrial contraction). As the atrium relaxes, the central venous pressure is reduced. 
The c-wave is produced by closure of the cuspidal valves and by the right ventricular contraction, because the 
increased ventricular pressure is transmitted backwards to the right atrium and large veins. Filling of the atrial 
chambers with blood is aided by the large atrial compliance. The v-wave relates to the venous return; throughout 
the ventricular systole and isovolumetric relaxation, venous blood returns to the heart, but the tricuspid valve is 
closed, so that the central veins and right atrium become distended. The coinciding pressure build-up is relieved, 
when the tricuspid valve opens at the start of diastole, and the pressure is reduced. (137, 138) Adapted from 
Wigger et al.
LAA has its developmental, ultrastructural, and physiological characteristics which are distinct 
from LA (22, 139-144). During the fourth week of embryogenesis, LAA is derived from the left 
wall of the primary atrium (145). LAA lies within the pericardium and it has a close relation to the 
left ventricle. It is not surprising that emptying and filling of LAA are significantly affected by left 
7ventricular function (143). The physiological properties and anatomical relations of LAA suggest 
that it is ideally suited to function as a decompression chamber during left ventricular systole and 
during other periods when left atrial pressure is high (146). These properties include the position of 
the LAA high in the body of LA; the increased distensibility of LAA as compared to LA; the high 
concentration of atrial natriuretic factor (ANF) granules contained within LAA; and the neuronal 
configuration of the LAA (147). 
A thrombus is likely to be formed in LAA in patients with AF, valvular disease or other condi-
tions with impaired blood flow in LAA (148, 149). The pathogenesis has not been fully elucidated; 
however, relative stasis which occurs in the appendage, owing to its shape and it’s inherent trabec-
ulations are all thought to play major roles (142, 144, 150). Obliteration or amputation of the LAA 
may help to reduce the risk of thromboembolism, but this may result in undesirable physiological 
sequelae such as reduced atrial compliance and a reduced capacity for ANF secretion in response 
to pressure and volume overload (151).
2.4.1 Heart rhythm
The contraction of the heart forms the intra- and extracardiac pressure gradients which establish 
the hemodynamics of the human circulation (9). A self-excitable sinoatrial node generates electrical 
impulses which induce a unified atrial contraction followed by the ventrical contraction delayed by 
about 0.1 seconds (152, 153). The sinus rhythm is most efficient in ensuring good blood circulation 
(154-156). 
2.4.1.1 Atrial fibrillation
AF is the most common sustained cardiac rhythm disturbance, increasing in prevalence with age 
(157). AF is defined as a cardiac arrhythmia with the following characteristics: the surface ECG 
shows irregular RR intervals, the surface ECG shows no distinct P waves, the atrial cycle length is 
usually variable and less than 200 ms (over 300 beat per minute) (158). AF is often associated with 
structural heart disease, most often caused by hypertension or coronary artery disease (159). 
Figure 2. Changes in manifestation of atrial fibrillation (AF) (Adjusted from European Society of Cardiology’s 
Guidelines for the management of atrial fibrillation) (158). The bottom line bars show a typical sequence of peri-
ods in AF against a background of sinus rhythm, and illustrate the progression of AF from silent and undiagnosed 
to paroxysmal and chronic forms, at times symptomatic (160, 161). The top line bars indicate therapeutically 
suitable actions. Light blue boxes relate to therapies that have proven effects on stroke (19). Red boxes indicate 
therapies that are currently used for symptom relief (162-165). Rate control is valuable for symptom relief (166-
172). A patient presenting AF for the first time is considered a patient with a first diagnosed AF (161, 173).
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8AF, which is self-terminating within 48 hours, is called paroxysmal AF. Spontaneous conver-
sion is rare when AF exceeds 48 hours. The stroke risk in paroxysmal AF is not different from that 
in persistent or permanent AF (174). Previously, a lone AF was considered to indicate AF where 
subsequent investigations could not demonstrate evidence of heart disease, but for many practi-
tioners it has become synonymous with ‘idiopathic AF’ (175).  Persistent AF is present when an AF 
episode lasts over a week or requires termination by cardioversion, either with drugs or by direct 
current cardioversion (176, 177). Long-standing persistent AF lasts for over a year (178). Permanent 
AF exists when the presence of the arrhythmia is accepted (179).  Silent or asymptomatic AF may 
manifest as an AF-related complication such as ischemic stroke or may be diagnosed by chance. 
Silent AF may also be presented as any of previous temporal forms of AF (161). Anticoagulation 
is considered for each patient on the basis of the CHA2DS2-VASc stroke risk stratification and the 
HAS-BLED bleeding risk stratification (180).
Hemodynamic impairment and thromboembolic events related to AF result in significant mor-
bidity, mortality, and costs (181). The risk of stroke is increased by fivefold in individuals with AF 
(148).  Both chronic/persistent and paroxysmal forms are equal in their possibility to induce cardi-
oembolism (174, 182). Synchronized electrical cardioversion or pharmaceutics can be used to con-
vert AF (183, 184). Surgical and catheter-based ablations are widely used to prevent the recurrence 
of AF and to decrease cardioembolic events (185).  Depending on stroke etiology, anticoagulation 
may be initiated to decrease the risk of recurrent stroke (186). 
2.4.1.2 Electrocardiogram and Holter monitoring
It is currently recommended that cardiac monitoring or 24-hour ECG Holter recording should be 
performed for at least the first 24 hours after an acute stroke (187). However, the detection rate 
of AF in 24-hour ECG Holter recording is not sufficient and it seems to be inferior also to three 
days’ serial ECG (188). The improved technology has made it possible to perform long-term cardiac 
rhythm monitoring for months or even years after a stroke onset (189).  In-hospital and outpatient 
telemonitoring as well as implantable loop recorder all seem to better at detecting AF than 24-hour 
ECG Holter monitoring, although success seems to vary depending on patient populations (104, 
190-201). 
2.4.2 Thrombus formation in the left atrial appendage
More than 150 years ago, Rudolf Virchow proposed that thrombus formation would need a series 
of events prior to its occurrence (202).  Today, it is generally recognized that Virchow’s triad con-
sists of the following events: endothelial or endocardial damage or dysfunction; abnormal blood 
stasis; and abnormal hemostasis, platelets, and fibrinolysis. The above variables are thought to 
increase risk for thrombus formation in AF. (203)
The LAA is the most common site of intra-atrial thrombus formation, not only in patients with 
AF but also in those without this condition (22, 151). Changes in LA and LAA dimensions and 
morphology can be associated with AF with a correlation to thromboembolism. LAA endothelial 
damage, especially in patients with AF, has been visualized in the electron microscope. (204) Mac-
roscopically a more wrinkled endocardium with an appearance attributable to edema and fibrous 
transformation but also LAA endothelial denudation and thrombotic aggregation have been linked 
with stroke and AF (205).
The LAA thrombus formation is influenced by the effectiveness of LAA contractility. AF is as-
sociated with decreased LAA contractile function (LAAEF ≤21%) and patients with AF require 
anticoagulant therapy in order to avoid thromboembolic events regardless of the absence of other 
causative risk factors (206). In addition decreased LA pump function has been shown to closely cor-
relate with LAA emptying velocity in cryptogenic stroke subjects nor receiving anticoagulation. In 
these patients, the levels of active phase inflammatory markers in plasma were significantly higher 
suggesting that impaired LAA and LA functions have a role in the pathophysiology of ischemic 
stroke (207).
Structural remodelling of LAA could contribute to the hypercoagulable state, by virtue of both 
enhanced blood stasis and an abnormal endocardium. Structural remodeling of the pectinate mus-
cles and multiple lobes of the LAA occur in patients with permanent AF. (208, 209) Morphologic 
LAA studies have shown larger volumes and luminal surface areas when compared to patients 
9without AF. Despite the increased LAA mean volume, both the absolute and relative surface areas 
of the pectinate muscles are reduced. In addition, there is a significant endocardial thickening with 
fibrous and elastic tissue. (208) Patients with AF have been demonstrated to have altered amounts 
of collagen degradation products and an impaired matrix degradation, with abnormal plasma 
concentrations of various matrix metalloproteinases, their inhibitors and growth factors (209-211). 
Further studies have identified disruption of various extracellular matrix components associated 
with arrhythmia and cardiac remodelling (212-215).
2.5 DIAGNOSTIC IMAGING OF ACUTE STROKE PATIENTS
Recombinant tissue plasminogen activator (rtPA) was approved over a decade ago for the treat-
ment of acute ischemic stroke. The rtPA treatment should be provided within four and half hours 
of stroke onset, preceded by a CT scan to exclude intracerebral hemorrhage, since intracerebral 
hematoma is a contraindication to the use of the rtPA. (216, 217) Although it is an efficient treat-
ment, it also has some drawbacks e.g. the incidence of intracranial hemorrhage in rtPA treatment 
is 6.4% (216, 218). This risk of this severe side effect has been shown to be even greater if strict 
adherence to the administration protocol has not not been followed. (219)  The progress for treat-
ing acute ischemic stroke has been slow and in addition, there are increasing demands for more 
safe and more feasible treatment procedures (220-224). Together with the exclusion of intracerebral 
hematoma, the conditions intra- and extracranial arteries are usually evaluated. Imaging of the 
vasculature greatly improves the localization of the site of vascular occlusion/stenoses. (225) The 
detection of an occluded artery is often crucial in determining the form of acute treatment (226). 
Intravenous thrombolysis appears more efficient for a distal than for a proximal thrombus whereas 
intra-arterial thrombolysis and mechanical thrombectomy are more efficient for the treatment of a 
proximal large-vessel occlusion (227). It is essential to diagnose the mechanism of ischemia as soon 
as possible in order to prevent recurrent stroke (228).
 
2.5.1 Imaging of the brain
CT and MRI are used for imaging of the density and intensity of the cerebral parenchyma and 
to gather information about anatomical structures of the damaged brain (220).  Imaging of acute 
stroke patients can be considered to serve three purposes, first the exclusion of hemorrhage, sec-
ond, the detection of the ischemic tissue, and third, the exclusion of conditions that may mimic 
acute cerebral ischemia (224, 229, 230). CT, as a first multidetectoral modality, can yield submil-
limeter slice thickness in a few seconds and with superior contrast resolution (231). During the 
past decade, the speed of MRI acquisition and reconstruction has increased and furthermore the 
quality of the images has improved, with the diversity of the pulsing sequences now being signifi-
cantly better (232). The development of diffusion-weighted imaging has provided the possibility to 
detect ischemic tissue within minutes after its occurrence (233). The precision of the fluid attenua-
tion inversion recovery (FLAIR) sequence has made it possible to visualize intraparenchymal and 
subarachnoid blood collections better than can be acquired with other sequences (234). The devel-
opments of gradient-echo imaging mean that one can detect acute parenchymal hemorrhage and 
thrombus formation (235, 236).
2.5.1.1 Exclusion of intracerebral hemorrhage
CT is considered to be the gold standard for the detection of intracerebral hematoma, although 
there are no studies which would have investigated with an immediate surgery or autopsy to de-
termine the sensitivity and specificity of CT in detecting acute intracerebral hematoma (231, 237).
In MRI, the appearance of the hemorrhage tends to vary due to both the age of the blood and the 
pulsing sequences being used (238-245). Magnetic susceptibility weighted imaging (SWI) is based 
on a T2-weighted MR sequence, which can be used to detect even small amounts of deoxyhemo-
globin. Other compounds, which can be well visualized on a T2-weighted MR sequence are those 
tissues containing iron or calcium. (241) In a study where 200 stroke patients first underwent gradi-
ent-echo MRI followed by non-enhanced CT imaging, both modalities were shown to be equivalent 
in detecting acute hemorrhage (96% concordance), although in fact in 49 patients intraparenchymal 
microbleeds were visualized with MRI but not with CT. When a gradient-recalled echo sequence 
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is used, MRI appears to be at least as accurate as CT in its ability to detect acute intracerebral 
hematoma. (242) Although the presence of old microbleeds may predict recurrent disabling and 
fatal strokes, there was no statistically significant increase in the risk of symptomatic intracerebral 
hematoma during thrombolysis in patients with less than five microhemorrhages detected on MRI, 
who were treated with intravenous thrombolysis (246).
2.5.1.2 Conventional evaluation of intracerebral ischemia
First sign of cerebral ischemia to be detected on CT within the first few hours after stroke onset 
is loss of gray-white matter differentiation due to the increase in the water concentration in the 
ischemic lesion (247-251). In addition, the distinction between the corpus striatum and other ba-
sal ganglia nuclei may be lost and cortical densities in the insula and over the convexities might 
blend (252). The swelling of the gyri may induce sulcal effacement, possibly leading to ventricular 
compression. The sooner that these signs become evident, the more profound will be the degree 
of ischemia (253-255). The extent to which the signs are observational depends on the infarction 
volume and the time gap between stroke onset to brain CT (256). There is a consensus that large 
infarcts with early swelling associate with more severe stroke but it is debatable whether the ad-
verse outcome after rtPA treatment may be induced by the parenchymal swelling (251, 252, 257). 
Within an optimal time window, severe early CT signs should not be used to exclude patients from 
receiving thrombolytic treatment unless the ischemic lesion exceeds one third of the middle cer-
ebral artery territory (257, 258). Another significant CT sign is that of increased density within the 
occluded vessel due to the thrombus (dense media sign), this sign is seen in almost half of all cases 
of angiographically proven thrombosis (259, 260). Unfortunately, the density of a small but occlud-
ing thrombus may vary due to arterial wall calcium, cerebrospinal fluid and fatty atheromatous 
material, and these factors complicate the determination of its composition (261). 
The most important MRI sequence with which to detect parenchymal ischemia is diffusion-
weighted imaging, based on the diffusion restriction when extracellular fluid excavates into the 
intracellular space (262). Diffusion-weighted imaging is known to be more advanced as compared 
to FLAIR and T2-weighted MRI, and much better compared to CT for detecting ischemic lesions 
within 6 hours from stroke onset (263, 264). While the diffusion sequence is T2-based, abnormalities 
including vasogenic edema may be misinterpreted (32, 265). The specificity of the technique can be 
increased by comparing the primary diffusion-weighted images with a diffusion coefficient map. 
Another option to visualize true restricted diffusion is to calculate the isotropic diffusion value of 
each pixel and divide this value by the T2 value. This will also eliminate the T2 shine-through. (266, 
267) Thus, the correlation with the apparent diffusion coefficient map, which reflects restricted 
diffusion as low intensity, greatly increases the specificity of the technique (268). It is important 
to remember that several conditions can produce restricted diffusion, such as infections, other in-
flammatory processes (e.g. multiple sclerosis), tumors with little amount of cytoplasm or with a 
complex internal architecture (269). 
2.5.1.3 Perfusion imaging
Decreased perfusion does not always cause ischemia, because ischemia is the metabolic result of 
the decreased delivery of energy-producing metabolites in relation to local metabolic demand (270-
274). In acute stroke, there are specific thresholds for a decreased cerebral blood flow, which predict 
tissue outcome. The identification of these thresholds is essential to operationally in order to define 
the penumbra. (275) Viable but non-functional tissue located adjacent to an ischemic infarct is de-
noted as the ischemic penumbra (276). For potential infarct expansion, it is not a predictor of how 
much expansion will actually occur but rather a qualitative marker of a larger perfusion abnormal-
ity than the diffusion weighted or perfusion volume map imaging lesion (277). It is believed that 
areas with a perfusion mismatch are present in at least 50% of stroke patients for up to 24 hours 
after the stroke onset (278, 279).
Perfusion imaging in acute stroke includes the identification of those brain regions with ex-
tremely low cerebral blood flow representing tissue which is irreversibly infarcted and is at in-
creased risk of hemorrhage if there is thrombolysis (280). Perfusion imaging also makes it possible 
to identify the brain regions that may be treated with thrombectomy or other active treatment 
procedures despite an apparently closed standard window for intravenous drug administration 
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(281-283). Perfusion imaging can be used for patient triage to other available therapies, such as drug 
induced hypertension or mechanical clot retrieval (284). This imaging modality may also help to 
make decisions regarding intensive monitoring of patients with large abnormally perfused brain 
regions. Perfusion imaging represents a biophysiologically based tool with which to assess patients 
who have awoken with a stroke and therefore the precise time of stroke occurrence is uncertain. 
(285) Earlier, diffusion imaging was combined with the use a diffusible tracer in single-photon 
emission CT and xenon-enhanced CT to enable the assessment of penumbra (286). If one assumes 
that there is no disruption of the blood-brain barrier, more novel non-diffusible tracers based on 
dynamic perfusion CT and perfusion MRI can be used (271, 280, 287, 288). There is evidence for 
a beneficial role of mismatch in extending the conventional time window for intravenous throm-
bolysis (289, 290). It has been demonstrated that intravenous rtPA can be administered safely and 
effectively for up to 6 hours after stroke onset when there is an MR diffusion/perfusion mismatch 
(291). Despite aforementioned results, intra-arterial therapy continues to have a role especially 
when treating stroke patients beyond the conventional time window (292-298).  There are a variety 
of treatment options for stroke patients qualified for endovascular intervention such as balloon an-
gioplasty, intra-arterial thrombolysis, stenting, aspiration, and mechanical maceration while novel 
therapies are continually emerging (299-304).
2.5.2 Imaging of the intracranial, carotid and vertebral arteries
The intra- and extracranial vasculature imaging is part of the first line diagnostics in patients with 
stroke or suspected cerebrovascular disease (305). Ultrasound has been primarily used to visualize 
the narrowing of extracranial arteries due to stenotic lesion (306). The current color Doppler flow 
imaging which is based on the direction of flow superimposes color-coded blood flow patterns 
over the B-mode template whereas power Doppler patterns color-codes blood flow according to the 
signal amplitude (307, 308). These latest modalities provide greater sensitivity to blood flow detec-
tion compared to prior ultrasound modalities, allowing for improved detection of narrow stenoses, 
tortuosity, and other abnormalities in the arterial wall (309, 310). Although carotid ultrasound is a 
safe and inexpensive technique, both its sensitivity and specificity appear to be lower than that of 
other modalities. In addition, carotid ultrasound can reveal only a small region of the carotid and 
vertebral arteries in the neck. (311)
While ultrasound has some advantages, CT angiography (CTA) has been shown to be an accu-
rate and safe and therefore CT has become a widely used technique to visualize occlusive lesions in 
extracranial and intracranial arteries (312). CTA is also capable of detecting intracranial aneurysms. 
CTA can readily be combined with imaging of cerebral parenchyma (313).  In general, CTA is equal 
or even superior in its accuracy to magnetic resonance angiography (MRA). In some cases, CTA’s 
overall accuracy exceeds even the catheter-based cerebral angiography. (314) CTA is comparable to 
digital subtraction angiography (DSA) when determining the degree of carotid stenosis in 88% to 
90% of cases. The differentiation of a very-high-grade stenosis from a total occlusion is especially 
important, because a high-grade stenosis can be opened either with surgery or with angioplasty 
plus stenting, whereas a total occlusion cannot be opened (315, 316). CTA has twice the spatial reso-
lution of MRA but only half that of DSA (317). As the number of rows of detectors increase, the spa-
tial resolution of CTA will start to approach that of DSA (317-320). The new CT scanner generations 
are enhancing the accuracy of this technique and at lower radiation doses (321, 322). However CTA 
does require the use of substantial amounts of intravenous contrast agent, and thus its application 
may be limited in patients with contrast allergies and renal dysfunction (323). 
MRA is often performed in combination with brain MRI in the setting of acute stroke to guide 
therapeutic decision making (232). A key clinical issue is the crelative sensitivity and specificity 
of MRA compared with conventional angiography or carotid ultrasound in the detection of vaso-
occlusive atherosclerotic lesions not only in extracranial vessels but also in the intracranial vessels 
(324-326). MRA is able to detect intracranial aneurysms and arteriovenous malformations and can 
also identify less common causes of ischemic stroke, such as arterial dissection, fibromuscular dys-
plasia, venous thrombosis, and some cases of vasculitis (327, 328). Despite its many advantages, 
MRA cannot be used in all patients with conventional pacemakers or metallic implants and its use 
is limited in claustrophobic patients (329). 
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2.5.3 Imaging of the heart
While a cardioembolic source of stroke remains frequently uncertain, the diagnosis of a cardiogenic 
stroke relies on the identification of a potential cardiac source of the embolism and on the absence 
of occlusive atherosclerotic disease (330). 
2.5.3.1 Cardiac ultrasound
Transthoracic echocardiography (TTE) and TEE have served as cornerstones in the cardiac evalua-
tion, diagnosis, and management of stroke patients (331). TTE is most often used for the detection 
of underlying cardiac pathology including myocardial infarct scars, valvulopathy, cardiomyopa-
thy or reduced ventricular function (332, 333). TEE is used to study the anatomy and function of 
LAA as well as and atrial septal anatomy (334, 335). TEE has also been used for investigating aortic 
arch atherosclerosis (336). TEE has been postulated to be relatively accurate tool for the detection of 
LAA and LA thrombi and is therefore the only recommended imaging modality for the evaluation 
of LAA in patients with AF (337, 338).  The identification of left atrial thrombi during transesopha-
geal echocardiographic examination has been compared with direct near-simultaneous visualiza-
tion during cardiac surgery, and it was reported to have 100% sensitivity, 99% specificity, 86% 
positive predictive value and 100% negative predictive value (339). A quadriphasic pattern of blood 
flow can be seen in the LAA, affording minimum blood stasis (142).
Despite these advantages, TEE may be uncomfortable, time-consuming and it is not always 
available especially in off-duty hours (340). Consequently, newer imaging modalities, such as car-
diac CT (cCT), have been tested and compared with TEE during the past decade to help in the 
diagnosis of LAA and LA thrombi (341).
2.5.3.2 Cardiac computed tomography
CT with ECG gating allows scanning the entire heart with a thin slice thickness and short effective 
exposure time resulting in images providing a high-resolution assessment of morphological detail 
of both the coronary arteries and the cardiac chambers (342). The cardiac anatomy is illustrated 
in reconstruction images that are created according to anatomic axes of the heart; Figure 3 shows 
reconstructions in the two-chamber view and Figure 4 illustates a transversal view. 
13
14
Upper left pulmonary vein
Aortic bulb
Upper vena cava
Left atrial appendage
Lower left pulmonary vein
Left atrial appendage
Left pulmonary veins
Coronary sinus
Left atrium
Mitral valve
Left ventricle
Papillary muscles
Apex
Figure 3. Reconstruction of two-chamber view (2CV). The white plane describes the horizontal orientation where 
the stack of CT slices was originally gained. When the oblique sagittal 2CV (red plane) was reconstructed, a plane 
perpendicular (yellow plane) to the mitral valve and parallel to the cardiac septum was obtained first, and then 
tilted from the left ventricle (LV) apex to the centre of the mitral annulus. Due to contrast agent injection, the 
LAA was visualized as a hyperdense structure surrounded by hypodense pericardial fat with high tissue contrast 
between the anatomical structures. The contrast media also opacified the left atrium (LA) and LV. The LAA bor-
ders were traced manually on the 2CV using the mitral valve annulus as a landmark with which to differentiate 
the LA from the LV.
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Left atrial appendageAortic bulb
Upper vena cava
Pulmonary trunck
Left atrium
Upper right
pulmonary vein
Aortic bulb
Upper vena cava
Pulmonary trunck
Left atrial appendage
Lower left pulmonary vein
Lower right
pulmonary vein
Figure 4. Reconstruction of transversal view (TV). The white plane describes the horizontal orientation where 
the stack of CT slices was originally gained. The TV (blue plane) was obtained from the horizontal slices. The left 
atrial appendage (LAA) borders were traced manually by using the two-chamber view stack and a localizer tool 
to differentiate the LAA orifice from the left atrium (LA) in the TV.
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It would be tempting if one could incorporate clonclusions from cCT to the initial evaluation of 
stroke patients in order to obtain an estimate of the risk of stroke recurrence. It has been postu-
lated that the combination of ECG-gated cardiac imaging with aortic and carotid artery imaging 
could serve as a ‘one-stop-shop’ for the etiological assessment of stroke patients with no need for 
further TEE or TTE evaluation. (343) There is evidence that there is good agreement between cCT 
and TEE for the detection of cardiac risk sources of embolism in stroke patients but also significant 
differences exist both in cardiac and aortic atheroma findings (344, 345). The diagnostic criteria for 
LAA thrombus between these studies differ because there are no established criteria for determ-
ing CT-revealed LAA thrombi (346). cCT has been shown to be moderately sensitive and highly 
specific for the detection of cardiac sources of emboli when it has been compared to the standard 
approach involving echocardiography, carotid ultrasonography, MR angiography of the neck and 
brain vessels (347). cCT has been found to be more sensitive than TTE in identifying previous myo-
cardial infarction scars (343). The current literature emphasizes that the performing both CT and 
echocardiography then more cardioembolic high risk findings can be found than by performing 
echocardiography alone resulting in reduced numbers of patients with cryptogenic stroke (348-
350). It appears that the more novel cCT technology improves the sensitivity of cCT detecting cardi-
oembolic risk sources (351). Moreover, the improved image quality especially in patients with high 
heart rates permits a more accurate assessment of LV function, further improving the possibilities 
of CT-based evaluation of patients with suspected cardioembolic stroke (352).
Arterial phase imaging results in a high contrast between LAA, LA or LV lumen and the endo-
cardium, allowing the visualization of intracardiac fine structures (353). Venous phase imaging, 
as performed approximately one minute after the contrast agent injection, helps in the differentia-
tion of LA thrombi from reduced LA flow without a thrombus (‘smoke phenomena’). With single 
scanning, cCT can achieve better differentiation of LV thrombus from papillary muscles but it still 
has sufficient tissue contrast to permit regional LV wall analysis. (354) Especially with old equip-
ment, the radiation dose needed for cardiac imaging is not negligible (343). When compared to the 
estimated increase in lifetime risk of cancer this risk seems to be acceptable against the high risk of 
recurrent stroke, should risk factors  not be recognized and appropriately treated (355). Moreover, 
the new low-dose techniques have achieved a major reduction in the radiation dose and imaging 
is conducted with doses below 1 mSv and with ultralow-dose scanners below 0.1 mSv (321, 322).
2.5.3.3 Cardiac magnetic resonance imaging
Routine cardiac MRI as a part of acute stroke diagnostic imaging is not included in the consensus 
guidelines but there is an increasing body of literature supporting its role as a possible adjunct 
method to echocardiography in selected patients (356). Cardiac MRI in stroke patients is indicated 
if TEE and TTE are not investigated for the presence of cardioembolic sources, or if there is sus-
picion of a cardiac tumor (357). In addition, cardiac MRI can provide an assessment of the great 
vessels as well as detection of small right-to left-shunts that may not be reliably evaluated with 
alternative methods (358).
While TEE is highly reliant on operator experience, cardiac MRI can be used as an alternative to 
evaluate the existence of LA or LAA thrombi (359). In comparison with TEE, MRI yields a sensitiv-
ity of 44%, specificity of 67%, positive predictive value of 80%, and negative predictive value of 29% 
(360). There are also studies which have describetd higher specificities and sensitivities for MRI in 
thrombus detection (341, 357, 359, 361). Cine MRI, resting perfusion and early and late gadolinium 
enhancement are some of the techniques that can be used to detect previous myocardial infraction, 
cardiac tumors and thrombi (362).
2.6 LEFT ATRIAL APPENDAGE MEASUREMENTS
Normal LAA volume has been studied previously from necropsy casts. In a study of LAA cast 
collection of 143 individuals without diagnosed atrial arrhythmias during their lifetime, the LAA 
mean volume was found to be 4.6 mL (362, 363). The overview of the three-dimensional (3D) imag-
ing studies concerning LAA volume measurements are shown in Table 1.
19
20
Study Group and Year Modality Group 1
Criteria N Age, years Rhythm LAA volume
Lee et al. 2013 (364) 144 55.2±12.0 PAF 4.9±2.4 mL/m2CT
Kimura et al. 2013 (365) No stroke/TIA 50 57.8±4.4 AF (49), PAF (31) 16.7±8.6 mLCT
Park et al. 2012 (366) No stroke/TIA 159 53.0±11.4 PAF 21.0±5.2 mLCT
Walker et al. 2012 (367) PAF 36 59±9.0 PAF 10.59±4.1 mLCT
Adams et al. 2012 (368) Post-ligation 12 64±12 AF (2.7±1.3 mL)CT
Erol et al. 2011 (369) Females 46 58, range 32-86 NSR 8.0±5.0 mLCT
Christiaens et al. 2010 (370) No cardiovascular disease 40 59±13 NSR 9±3 mLCT
Yamaka et al. 2009 (371) Bypass surgery 16 66.5±9.3 NSR 8.4±4.7 mLCT
Lacomis et al. 2007 (372) Females 10 - PAF 13±5 mLCT
Burell et al. 2013 (373) No stroke 48 64.8±8.7 AF/PAF 21.7±8.27 mLMRI
Di Biase et al. 2012 (374) No stroke/TIA 854 58±10 AF/PAF 14.13±6.04 mLMRI
Beinart et al. 2011 (275) No stroke 126 53.4±9.8 AF 14.5±7.1 mLMRI
Anselmino et al. 2011 (376) PAF 288 - PAF 13.0±6.1 mLMRI
Tanaka et al. 2014 (377) NSR 79 71.8±11.2 NSR 3.14±2.04 mL/m23D TEE
Ono et al. 2012 (206) No thrombus 125 62.1±9.6 AF 10.2±4.7 mL3D TEE
Chen et al. 2012 (378) No AF 34 - NSR 5.7±3.8 mL3D TEE
Nakajima et al. 2010 (379) NSR 55 - NSR 8.1±5.1 mL3D TEE
Valocik et al. 2002 (380) End-systole 45 59.5±14.4 NSR (29), AF (16) 9.9±7.3 mL3D TEE
Table 1. Overview of the three-dimensional imaging studies concerning left atrial appendage
LAA-EF ≥58 cm/s
CT, computed tomography; MRI, magnetic resonance imaging; 3D TEE, three-dimensional transesophageal 
echocardiography; LAA, left atrial appendage; LAA-EF, left atrial appendage ejection fraction; TIA, transient 
ischemic attack; PAF, paroxysmal atrial fibrillation; NSR, normal sinus rhythm; AF, atrial fibrillation; ns, not sig-
nificant
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Group 2 P Age P LAA volume
Criteria N Age, years Rhythm LAA volume
LAA-EF <58 cm/s 142 58.5±10.3 PAF 5.6±2.5 mL/m2 0.012 0.017
Stroke/TIA 30 59.9±7.8 AF (5), PAF (25) 15.1±5.2 mL ns. ns.
Stroke/TIA 17 63.2±5.7 PAF 23.5±3.5 mL <0.001 0.054
AF 23 61±6.8 AF 16.53±7.1 mL ns. <0.001
Pre-ligation 12 64±12 AF 14.0±8.3 mL - 0.005
Males 60 52, range 8-77 NSR 6.1±3.0 mL - 0.024
Cardiovascular disease 80 65±13 NSR 11±6 mL <0.05 ns.
Maze procedure 23 65±13 AF 16.9±7.3 mL ns. 0.01
Males 15 - PAF 19±8 mL - ns.
Stroke 48 70.0±8.7 AF/PAF 28.8±13.5 mL 0.0045 0.002
Stroke/TIA 78 62±8 AF/PAF 15.04±7.10 mL 0.304 0.372
Stroke/TIA 18 62.0±7.6 AF 22.9±9.6 mL <0.001 <0.001
AF 185 - AF 14.3±6.2 mL - 0.022
PAF 23 73.7±9.0 PAF 4.78±3.00 mL/m2 ns. 0.003
Thrombus 15 65.3±9.0 AF 17.9±8.1 mL ns. <0.001
AF 62 - AF 7.4±4.1 mL - <0.01
AF 46 - AF 10.5±5.9 mL - 0.03
End-diastole 45 59.5±14.4 NSR (29), AF (16) 13.8±8  mL - -
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In a previous cCT study in patients without AF, the normal LAA mean volume was measured in 
three different phases of the atrial cycle. When the LA volume was at its maximal, LAA was found 
to be 9 mL (6–20 mL), whereas during atrial diastasis the LAA volume was 6 mL (6–13 mL) and 
when the LA volume was at its minimal LAA volme was reduced 3 mL (3–11 mL). This result was 
based on volumes from only a small number of patients (n=10) (372). In another study of 25 normal 
subjects without AF, LAA maximal volume at end-systole was 6.5±1.9 mL (Table 2) (381). In a third 
study, LAA mean maximal volume measured at end-systole was 9±3 mL, and the normal LAA 
mean minimal volume measured at end-diastole was 4±2 mL. This study was carried out with 40 
patients without AF or coronary artery disease (370).  In two previous studies, males were reported 
to have larger LAAs although this difference did not achieve statistical significance (370, 372).
Group
Control
Volume, mL P
Left atrium
131±31
AF 154±44
Long-term AF 161±21
Left atrial appendage 6.5±1.9
8.1±2.5
10±5.1
11±3.8
Table 2. Left atrium and left atrial appendage volume in patients with sinus rhythm (NSR; n=24), paroxysmal atrial fibril-
lation (PAF; n=61), persistent atrial fibrillation (AF, n=35) and long-term persistent AF (n=19); CT reconstruction was per-
formed at end-systole (Nedios et al. 2011) (381) 
PAF
95±18
0.007
0.49
0.004
0.047
0.62
0.001
Control
AF
Long-term AF
PAF
CT, computed tomography
In the first two of the above studies, there were also patient subgroups suffering from AF. In the 
first report, 25 patients with PAF were found to have an LAA mean volume of 16 mL (11 – 75 mL) 
during LA maximum volume, LAA mean volume of 13 mL (11 – 51 mL) during LA diastasis and 
LAA mean volume of 8 mL (5 – 47 mL) during LA minimum volume. The same study included also 
a non-ECG gated series of persistent AF patients (n=10), there were found to have an LAA volume 
of 23 mL (17 – 70 mL) (372).  In the second study, where the analyses were performed at end-systole, 
the mean LAA volumes of 8.1±2.5 mL for patients with PAF (n=63), 10.0±5.1 mL for patients with 
persistent AF (n=34) and 11.0±3.8 mL for patients with long-term persistent AF (n=18) were found 
(381). Accordingly, the MRI studies seem to indicate that patients with AF (14.3±6.2 mL; 17.3±6.7 
mL) or PAF (13.0±6.1 mL) have larger LAAs than compared to patients without AF (376, 382). There 
is also another study describing a similar result utilizing 3D TEE carried out in 55 patients without 
diagnosed AF (LAA volume 8.1 ± 5.1 mL [2.8–27.4]) and 46 patients with AF (LAA volume 10.5 ± 
5.9 mL [3.8–30.5]) (379). It was reported that silent cerebral ischemia, although this is tought to be 
manifestated via AF bursts, did not affect the LAA volume (mean LAA volume 8.0±4.4 mL) (383).
Table 3 shows LAA volume in the phases of cardiac cycle accordingly to studies cinducted in 
seven patients with AF and 10 patients in sinus rhythm (384). There are also other studies which 
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indicate that the LAA volume in cCT is significantly greater in patients with persistent AF as com-
pared to patients with PAF (385, 386).
LAA Volume in AF Patients (n=7) P
Atrial contraction
7.24±2.80 mL
8.14±2.97 mL
8.89±3.50 mL
Late-systole 9.46±3.43 mL
8.96±3.12 mL
8.59±3.30 mL
8.24±3.10 mL
Table 3. Left atrial appendage volume in ten phases of cardiac cycle (Saremi et al. 2008) (384)
6.85±3.01 mL
0.0134
0.0221
0.0351
0.0316
0.0460
0.01870%
20%
30%
10%
40%
60%
70%
50%
LAA Volume in NSR Patients (n=10)
15.7±6.49 mL
16.2±6.96 mL
16.9±7.43 mL
17.4±7.76 mL
17.3±7.94 mL
15.7±7.46 mL
14.9±6.08 mL
15.2±6.93 mL
14.3±6.07 mL
14.5±5.87 mL
8.54±3.08 mL
8.48±3.10 mL 0.0341
0.0462
0.0288
0.0263
80%
90%
Early-diastole
Mid-diastole
Late-diastole
Cardiac Phase
LAA, left atrial appendage; AF, atrial fibrillation; NSR, normal sinus rhythm
There are no previous studies which have investigated LAA volume in cryptogenic stroke pa-
tients. However. in one of the previous cCT studies, patients with both stroke and AF had an LAA 
volume of 28.8±13.5 mL while patients without stroke but with AF had an LAA volume of 21.7±8.3 
mL (373).
There are also were few studies which have examined the LA volume in patients with cryp-
togenic stroke. Based on LA diameter measurements, LA enlargement has been found in only 6.7% 
of stroke/TIA patients, but contradictory results have also been reported (151, 334).  It seems that 
three-dimensional volume measurements provide more accurate results and narrower limits for 
normality, due to their higher measurement accuracies (23, 387).
There is a relatively little known about the measurement reproducibility of LAA and LA vol-
umes (369).  One previous study with cCT tested the interobserver variability of the LA measure-
ments in 70 randomly selected patients, Bland-Altman plots did not reveal that any significant bias 
would be associated with LA size (388). In another study, 3D threshold based end-diastolic volume 
measurements yielded 0.961–0.997 intraclass correlation coefficients (ICC) in intra-observer and 
0.867–0.926 ICC in interobserver analyses (389). In a study comparing a 320-slice cCT and transtho-
racic 2D and 3D TTE, both techniques showed a strong positive correlation, but interestingly the 
absolute value of LA volume by cCT was significantly larger than that determined by either 3D or 
2D TTE. This may be due to either overestimation by cCT, underestimation by TTE, or both (390). 
The intra-observer correlation coefficients among 20 randomly selected patients were 0.94 and 0.93 
for the measurement of the LA and LAA volumes, respectively and the respective inter-observer 
correlation coefficients were 0.93 and 0.92 (381).
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2.6.1 Left atrial appendage volume as a risk factor for ischemic stroke
AF seems to promote LA dilatation, thus amplifying the potential for hemodynamic stasis (391). 
In patients with AF, spontaneous echo contrast has been shown to independently associate to an 
increased risk of cardiogenic stroke (392). Dilatation of LA is associated with thrombogenesis in 
LAA or LA, indicating that the LA volume, when corrected for body surface area, would be an in-
dependent risk factor for stroke (393, 394). The risk of emboli increases with age and the reduction 
in cardiac index, but it seems to correlate poorly with the clinical classification of stroke severity. An 
initial embolic event is highly predictive for recurrent cardioemboli (395). There is no evidence that 
there would be any the correlation between LAA emptying velocities and clinical characteristics or 
imaging findings, which underlines the independence of LAA volume from many other risk factors 
of stroke (396). It is important to note that previous studies imply that there is a poor correlation 
between LAA and LA volumes emphasizing the importance of conducting separate LA and LAA 
evaluations (379, 397, 398). Figure 5 illustrates the extensive variation of LAA volume in relatively 
healthy patients and Figure 6 illusrates the variation of LAA volume in acute stroke patients.
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Figure 5. Distribution of maximum left atrial appendage volume in 106 patients who underwent coronary artery 
CT for other reasons than occlusive coronary artery disease or stent/bypass graft evaluation (Erol et al. 2011) 
(369). 
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Figure 6. Two-chamber views from the hearts of four acute stroke patients, who underwent profound clinical 
investigations to define the etiology of stroke. 
A.) Relatively young (45 years) and previously healthy male patient with a normal sized (4.70 mL; 2.04
  mL/m2) left atrial appendage (LAA). The overall length of LAA is long, but the LAA lumen is narrow and
  pointing upwards. Despite severe stroke symptoms, no etiological mechanisms could be identified. 
B.) Sixty-one year-old male patient with normal sized (6.09 mL; 2.93 mL/m2) LAA. If the LAA volume had been 
measured from only one slice, then the volume analysis would have overestimated the true LAA volume. 
C.) Seventy-six year-old male patient with large (19.35 mL; 10.66 mL/m2) LAA. A thrombus is seen as a re-
markable, hypodense (darker) area inside the distal part of LAA, because the gadolinium contrast agent 
concentration is lower in LAA than in pathologically intact parts of the heart.
D.) Fifty-six year-old male patient with hypertension. Patient has very large (26.29 mL; 12.72 mL/m2) LAA. 
Atrial fibrillation was not detected with a 24 hour electrocardiography Holter evaluation. The patient was 
diagnosed as having cryptogenic stroke.
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Cardiac MRI studies of AF patients have revealed that the LAA volume is associated with an 
increased prevalence of previous stroke but LAA neck measurements displayed an even clearer 
correlation with that risk (379, 397, 398).  In contrast, there is evidence on emerging from a large 
multi-center study that different LAA morphology in AF patients but not LAA size itself would 
be a predictor for stroke (374). There is one study conducted in AF patients which supports the 
view that LAA volume is a predictor of stroke without there being any correlation between LAA 
morphology and stroke risk or any other imaging parameters. That study suggested that there may 
be a threshold for LAA volume that could direct clinical decision making. The LAAs in the smaller 
quintiles exhibited only a modest increment in stroke risk but LAA volume became a powerful 
predictor of risk in the upper quintile. Those patients with LAA volume of >34 cm3 seemed ti be at 
a significantly increased stroke risk (373). The data indicated that LAA volume had similar ability 
to predict stroke risk as the clinical measures such as CHADS2 score and the expanded CHA2DS2-
VASc score (399).
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3 Aims of the study
 
The general aim of this thesis was to assess LAA volume in acute ischemic stroke patients without 
clinically significant carotid/vertebral artery stenosis or known AF.
The specific aims were:
1.)  To study the reproducibility of LAA and LA volume measurements.
2.)  To evaluate the LAA volume in acute cryptogenic stroke patients with cCT.
3.)  To assess which factors would associate with the increase in the LAA volume.
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4 Morphological and volumetric analysis of left 
atrial appendage and left atrium
 
4.1 ABSTRACT
4.1.1 Objectives
Left atrial appendage (LAA) dilatation and morphology may influence an individual’s risk for in-
tracardiac thrombi and ischemic stroke. LAA size and morphology can be evaluated using cardiac 
computed tomography (cCT). The present study evaluated the reproducibility of LAA volume and 
morphology assessments.
4.1.2 Methods
A total of 149 patients (47 females; mean age 60.9±10.6 years) with suspected cardioembolic stroke/
transient ischemic attack underwent cCT. Image quality was rayed according to a four category 
subdivision categories. Ten patients were selected from each image quality category (n=40) for 
volumetric reproducibility analysis by two individual readers. LAA and left atrium (LA) volume 
were measured in both two-chamber (2CV) and transversal view (TV) orientation. Intertechnique 
reproducibility was assessed between 2CV and TV (200 measurement pairs). LAA morphology 
(A=Cactus, B=ChickenWing, C=WindSock, D=CauliFlower), LAA opening height, number of LAA 
lobes, trabeculation, and orientation of the LAA tip were analysed in all study subjects by three 
individual readers (447 interobserver measurement pairs). The reproducibility of volume measure-
ments was assessed by intra-class correlation (ICC) and the reproducibility of LAA morphology 
assessments by Cohen’s kappa.
4.1.3 Results
The intra-observer and interobserver reproducibilities of LAA and LA volume measurements were 
excellent (ICCs>0.9). The LAA (ICC=0.954) and LA (ICC=0.945) volume measurements were com-
parable between 2CV and TV. Morphological classification (ĸ= 0.24) and assessments of LAA open-
ing height (ĸ=0.1), number of LAA lobes (ĸ=0.16), trabeculation (ĸ=0.15), and orientation of the LAA 
tip (ĸ=0.37) was only slightly to fairly reproducible. 
4.1.4 Conclusions
LA and LAA volume measurements on cCT provide excellent reproducibility, whereas the visual 
assessment of LAA morphological features is challenging and results in unsatisfactory agreement 
between readers.
4.2 INTRODUCTION
 
Stroke is the leading cause of long-term disability and the second highest cause of mortality glo-
bally (400). The currently recognized mechanisms for ischemic stroke or transient ischemic attack 
(TIA) are embolism, local vascular thrombosis, and decreased brain tissue perfusion due to other 
reasons (401). Cardioemboli are derived mainly from the left atrial appendage (LAA) (402). Even 
although atrial fibrillation (AF) being the most common risk factor for cardioembolism, it is not 
always recognized during acute cardioembolic events (127). For example, one out of every three 
ischemic strokes/TIAs remains undetermined. The role of LAA enlargement in the etiology of these 
strokes may be underestimated, and cryptogenic stroke/TIA has been associated with enlarged 
LAA volumes (403, 404). The role of the LAA in thrombus formation and stroke risk has been 
studied using multiple imaging modalities (13, 147, 374, 375, 405-407).  Recent magnetic resonance 
imaging (MRI) studies have revealed that the LAA volume is strongly associated with an increased 
prevalence of prior stroke/TIA, and the risk differs between LAA morphologies (374, 375). Percuta-
neous LAA occlusion provides the advantage of being a minimally invasive treatment for patients 
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in whom long-term anticoagulation treatment is deemed unsuitable and may be equivalent to treat-
ment with oral anticoagulant agents in those individuals considered at moderate-to-high risk of 
suffering thromboembolism (408). There is increasing evidence indicating that the upper quintile 
of the LAA volume is a powerful predictor of stroke risk (373). The availability of novel low-dose 
computed tomography (CT) scanners may increase the dendency to use cardiac CT (cCT) for both 
etiological assessment and risk stratification (409). Although 2D transesophageal echocardiogra-
phy (TEE) is currently the most commonly utilized imaging modality in the preoperative assess-
ment, the use of 3D approaches has been shown to provide asupplemental information in cases of 
complex morphology of the LAA (378).
The value of a measurement method is largely dependent on its ability to provide reproducible 
and reliable results. To the best of our knowledge, the magnitude of these errors in the assessment 
of LAA volume and morphology by cCT has not been fully elucidated. We analysed the intra-
observer and interobserver reproducibility of LAA and left atrium (LA) volume measurements in 
the transversal (TV) and two-chamber view (2CV) orientations and evaluated the repeatability of 
visual assessments of the morphological features of the LAA.
4.3 METHODS
This study was part of the EMBODETECT project (404) and has been approved by the Kuopio Uni-
versity Hospital Research Ethics Board with all clinical investigation being conducted according 
to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained 
from the participants or their legally authorized representative if a patient was unable to provide 
consent due to impaired mental or physical function caused by the stroke.
4.3.1 Study design and population
Acute stroke/TIA patients admitted to the university hospital between March 2005 and November 
2009 were evaluated as candidates for this cCT study. The neurologists involved in the study re-
cruited 162 patients (47 females; mean age 60.9±10.6 years) with suspected cardioembolic stroke/
TIA without known atrial fibrillation. Thirteen patients were excluded for the following reasons: 
cCT image quality was not appropriate for analysis of LAA size (n=4), ECG synchronization was 
not used for cardiac imaging (n=3), contrast media injection failed (n=2), use of contrast media was 
contraindicated due to decreased renal function (n=1), or the patients refused to participate after 
providing informed consent (n=3). The remaining 149 patients were included in the present study.
4.3.2 CT imaging
Contrast-enhanced cCT was performed with a 16-slice (n=113 patients) or 64-slice (n=36 patients) 
scanner (Somatom Sensation 16 and Somatom Definition AS; Siemens Medical Solutions, Forch-
heim, Germany). Prior to imaging, β-adrenoreceptor antagonists were not administered. The aor-
tic arch and cervical and intracranial arteries were scanned first, immediately followed by the as-
cending aorta and heart. When using the 16-slice scanner, contrast agent was injected through an 
18-gauge catheter into the antecubital vein at 5 mL/s, followed by a 50-mL injection at 2 mL/s and 
subsequent 20-mL saline chaser. With the 64-slice scanner, 100 mL of contrast agent (350 mg/mL) 
was injected at 5 mL/s, followed by a 20-mL injection at 2 mL/s and subsequent 20-mL saline chaser. 
Cardiac imaging was performed during mid-diastole in all study subjects. In the 16-slice scanner, 
collimation was 16×0.75 mm, with  a rotation time of 0.42 s, and tube potential of 120 kV; the cur-
rent was set to 500 mAs for the first 80 patients and reduced to 250 mAs thereafter. In the 64-slice 
scanner, collimation was 64×0.6 mm, the rotation time was 0.33 s, and the tube potential was 120 
kV; the reference current was set using commercially available tube current modulation software 
(CAREDose4D, Siemens Medical Solutions) at 160 mAs for the first 15 patients and then reduced to 
100 mAs. Mid-diastolic 0.75 to 1.0-mm-thick slices with 20–25% overlap were reconstructed.
4.3.3 LAA and LA volume measurements
Quantitative image analysis was performed on an IDS5 diagnostic workstation (version 10.2P4; 
Sectra Imtec, Linköping, Sweden) using magnified images on 1024×768 and 1600×1200 displays. 
The oblique sagittal 2CV was obtained perpendicular to the mitral valve and parallel to the cardiac 
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septum, and set from the left ventricle (LV) apex to the centre of the mitral annulus. The TV was 
obtained from horizontal slices. Due to contrast agent injection, the LAA was seen as a hyperdense 
structure surrounded by hypodense pericardial fat with high tissue contrast between the anatomi-
cal structures. The entire LAA was fully opacified with contrast media in all study subjects. The 
LAA borders were traced manually on the 2CV and TV using the mitral valve annulus as a land-
mark to differentiate the LA from the LV. The 2CV stack and localizer tool were used to differentiate 
the LAA orifice from the LA in the TV. Planimetration of the entire LAA comprised a mean 10.4±2.0 
slices in the 2CV and 10.8±1.9 slices in the TV, whereas planimetration of the entire LA consisted 
of mean of 20.0±3.2 slices in the 2CV and 17.6±2.9 slices in the TV. Volumes were calculated using 
Simpson’s method by multiplying the area of each manually traced LAA and LA by the section 
thickness (3 mm) and summing the volumes of the separate sections. 
4.3.4 Intra-observer and interobserver reproducibility of volume measurements
All observers were guided by a cardioradiologist. Observer 1 performed planimetration in both the 
2CV and TV. Image quality was rated as excellent, good, moderate, or poor. Forty patients were 
selected for reproducibility analysis based on representative image quality, resulting in 10 scans 
being selected from each of the four categories. To calculate intra-observer repeatability, the ob-
server reconstructed new slices in both orientations and repeated the LAA and LA measurements 
one month later while blinded to the previous measurements. In the interobserver reproducibility, 
Observer 2 reconstructed new slices and analysed the LAA and LA volumes of the same 40 patients 
in both orientations (Figure 7).
4.3.5 LAA morphology analysis
As originally described by Wang et al (374, 386), the shape of the LAA was classified as: A) Cactus, 
B) ChickenWing, C) WindSock, or D) CauliFlower (365). The Cactus is defined as a dominant cen-
tral lobe, limited overall length, and one or more secondary lobes; ChickenWing as a main lobe that 
bends from the proximal middle part of the LAA; WindSock as one dominant lobe with several 
secondary, or even tertiary, lobes; and CauliFlower as limited overall length and complex internal 
structures. The opening height of the LAA compared to the mitral annulus, the number of LAA 
lobes, the amount of intra-LAA trabeculation, and the orientation of the tip of the LAA were clas-
sified into three categories. 
4.3.6 Interobserver reproducibility of LAA morphological assessments
Three independent observers (Observers 1, 3, and 4) reconstructed the 2CV and visually analysed 
LAA morphology while blinded to collateral readings. Consequently, the reproducibility of visual 
classifications of LAA morphology was assessed with 447 independent classifications made by 
three observers (Figure 7).
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Figure 7. Study design of left atrial appendage (LAA) and left atrium (LA) volume reproducibility analyses and 
morphological assessment of LAA. Ob, Observer; TIA, transient ischemic attack; 2CV, two-chamber view; TV, 
transversal view; morpho, morphology.
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4.3.7 Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) and categorical variables 
as absolute values and percentages. Spearman’s correlation coefficient was used to evaluate the 
associations between continuous variables. Significance was set at P<0.05 and highly significant 
at P<0.01. In the volumetric analyses, intraclass correlation coefficients (ICC) were calculated us-
ing a two-way mixed-effects model with absolute agreement to assess the interobserver and intra-
observer reproducibility in both orientations and between different orientations across all four im-
age quality categories. ICC values from 0.0 to 0.2 as were considered negligible, from 0.2 to 0.4 as 
very low, from as 0.4 to 0.7 moderate, from 0.7 to 0.9 as high, and from 0.9 to 1.0 as very strong. 
Interobserver and intra-observer coefficients of variability (CV%) were assessed to evaluate the 
volume diversity across image quality categories for both readers in both orientations and between 
different orientations. CV% was calculated by dividing the SD of the differences by the mean of 
the parameter under consideration. In the current study, group variability with a CV% <8% was 
considered homogenous, from 8 to 10% average, and >12% diverse. Based on the normal distribu-
tion in the Kolmogorov-Smirnov test, the Mann-Whitney U test was used to compare the ICC and 
CV% in dichotomous variables and the Kruskal-Wallis test in polytomous variables. The correla-
tion between the ICC and CV% was measured to evaluate whether reproducibility is associated 
with volume diversity. Bland-Altman plots were created to exclude systematic bias depending 
on LAA and LA volume or the observers. Cohen’s kappa was used to quantify the interobserver 
measurements for LAA morphology assessments; kappa values from 0.0 to 0.2 were considered as 
slight, from 0.2 to 0.4 as fair, from 0.4 to 0.6 as moderate, from 0.6 to 0.8 as substantial, and from 
0.8 to 1.0 as near perfect (410). Data were analysed using SPSS for Windows (version 19, 1989–2010 
SPSS Inc., Chicago, USA).
4.4 RESULTS
4.4.1 Patient characteristics and image quality
The characteristics of all 149 patients included in the morphological analyses and the 40 patients 
the included in different types of reproducibility analyses are shown in Table 4. The mean radiation 
dose was 10.0±3.5 mSv (range 2.0–16 mSv). Image quality was rated as excellent in 22 (61%), good in 
8 (22%), moderate in 6 (17%), and poor in 0 (0%) of the 36 patients imaged with the 64-slice scanner, 
and correspondingly in 8 (7%), 34 (30%), 45 (40%), and 26 (23%) of the 113 patients imaged with the 
16-slice scanner. All investigated patients were in sinus rhythm when the cCT scan was performed. 
There was no association between heart rate and CV% nor any correlation between image quality 
and heart rate.
4.4.2 Reproducibility of LAA and LA volume measurements
The results of the interobserver and intra-observer reproducibility analyses of LAA and LA volume 
measurements are shown in Table 5. Based on ICC values, reproducibility was very high despite 
variations in image quality. Volumetric measurements in 2CV and TV resulted in excellent compa-
rability (Table 6).
When combining all reproducibility analyses, the CV% values did not indicate significant vol-
ume diversity in interobserver and intra-observer analyses, intertechnique analyses between 2CV 
and TV, or analyses according to image qualities (Table 5). A significant (correlation coefficient = 
-0.817; P<0.01) negative correlation was observed between the ICC and CV%.
The Bland-Altman plots in Figure 8 show that the reproducibility of LAA and LA volume 
measurements does not depend on the volume. No systematic difference between image quality 
or measurement orientations was observed. The Bland-Altman plots in Figure 9 reveal that no 
systematic bias has been introduced due to different readers for volume measurements in the 2CV 
or TV orientation.
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149 Patients
Age, yr
11 (38.2)
29.2±4.0
2.0±0.2
Caucasian race, n (%) 40 (100.0)
21 (52.5)
18 (45.0)
3 (7.5)
Table 4. Clinical characteristics of patients
60.1±9.7
40 Patients
47 (31.5)
28.1±4.4
2.0±0.2
149 (100.0)
88 (59.1)
61 (40.9)
22 (17.8)
60.9±10.6
29 (19.5)
38 (25.5)
5 (12.5)
7 (7.5)
Hyperlipidemia, n (%)
Diabetes, n (%)
Smokers, n (%)
Characteristic
Females, n (%)
Body mass index, kg/m2
Body surface area, m2
Hypertension, n (%)
Prior myocardial infarction, n (%)
Prior stroke, n (%)
4 (10.0)19 (12.8)
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Table 5. Interobserver and intraobserver reproducibility analysis of left atrial appendage and left atrium volumes
Two-chamber view
CV%ICC
0.978
CV%
10.1
13.3
18.2
ICC
0.970
0.927
0.978
0.960
0.929
12.3
13.5
0.988
0.984
0.995
0.988
6.0
9.1
5.5
5.0
6.4
Left Atrial Appendage
Interobserver Intraobserver
CV%ICC
0.998
CV%
4.3
4.6
11.1
ICC
0.987
0.946
0.972
0.996
0.977
6.9
6.7
0.988
0.996
0.989
0.992
1.7
3.6
3.1
5.2
3.4
Left Atrium
Interobserver Intraobserver
Average
Total
Excellent
Good
Poor
Transversal view 0.9395.3
21.0
8.6
0.943
0.972
0.946
0.953
0.976
17.2
13.0
0.988
0.984
0.954
0.970
8.1
8.2
8.0
13.7
9.5
0.9958.3
8.9
9.0
0.948
0.970
0.905
0.944
0.967
14.5
10.2
0.979
0.998
0.985
0.989
3.3
5.8
2.8
5.5
4.3
Average
Total
Excellent
Good
Poor
Forty measurements pairs included 10 patients from each image quality category.
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Table 6. Intertechnique reproducibility of left atrial appendage and left atrium volume measurements
Left Atrial Appendage Left Atrium
Excellent
CV%
9.8
ICC
0.963
0.957
0.953
0.949
0.917
13.5
12.1
14.1
13.0
CV%
7.3
ICC
0.944
0.949
0.930
0.931
0.965
8.0
9.8
10.6
9.4
50
80
50
50
50
0.957
0.954
12.0
12.4
0.955
0.945
8.6
8.9200
120
Average
Interobserver
Good
Poor
Total
Intraobserver
Image Quality Measurement Pairs, N
Two hundred measurement pairs: 80 pairs with different observers and 120 pairs with the same observer.
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Figure 8. Bland-Altman plots show the reproducibility of 40 left atrium and 40 left atrial appendage volume meas-
urements with the same observer and with different observers in the two-chamber view and in the transversal 
view. X-axis shows the mean of two volume measurements and the y-axis displays the difference between re-
spective measurements. The middle line corresponds to the mean difference and the outer lines correspond to the 
95% confidence interval. Filled squares  (■) represent cardiac computed tomography images with excellent image 
quality; filled circles (●), good image quality; empty circles (◌), moderate image quality and empty squares (□), 
poor image quality, respectively. Volume size or image quality have no significant influence on inter- or intraob-
server measurements in either orientations.
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Figure 9. Bland-Altman plots show intertechnique reproducibility of 200 left atrium and 200 left atrial appendage 
volume measurements performed in the two-chamber view or transversal view orientations. X-axis shows the 
mean of two volume measurements and y-axis represents the difference between respective measurements. The 
middle line corresponds to the mean difference and the outer lines correspond to the 95% confidence interval. 
Filled circles (●) illustrate 80 interobserver and empty circles (◌) illustrate 120 intraobserver measurements per-
formed in the two orientations. Volume size or observer have no significant influence on measurements.
 
4.4.3 Reproducibility of LAA morphological assessments
Cohen’s kappa value indicated fair agreement between observers in the assessment of LAA mor-
phology (ĸ=0.24) and LAA tip orientation (ĸ=0.37), and slight agreement between observers in the 
assessment of LAA opening height (ĸ=0.1), the number of LAA lobes (ĸ=0.16), and the amount of 
trabeculation (ĸ=0.15).
4.5 DISCUSSION
The main finding of the current study was that LAA and LA volume measurements obtained with 
cCT are highly reproducible and comparable between observers, despite differing image quality, 
variation in LAA or LA volumes, and differing measurement orientations. Visual classification 
of LAA morphology into four classes (Cactus, ChickenWing, WindSock, or CauliFlower) and the 
evaluation of LAA tip orientation had fair interobserver reproducibility. However, the more de-
tailed visual classifications of other morphological features were unsatisfactory, resulting in only 
slight agreement between the readers. 
The detection of an enlarged LAA in patients with acute ischemic stroke/TIA may be useful in 
the risk stratification of recurrent stroke. Recent multicentre studies have shown that patients in 
the highest LAA volume quintile are at an increased risk of suffering cardioembolic events (373). 
In addition, increased LAA and LA volumes have been detected in patients with AF and paroxys-
mal AF, but also cryptogenic patients with no obvious etiology for stroke/TIA (366, 375, 381, 404). 
Some studies have also speculated on whether certain LAA morphology types increase the risk for 
thrombus formation (374, 386, 411). 
In the future, not only stroke/TIA, but also AF diagnostics and treatment, may benefit from the 
accurate evaluation of LAA or LA volume (366, 381, 386, 411). However, if these are to be clinically 
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feasible, the assessments should be highly reproducible. Though considered to be haemodynami-
cally more vivid, the main interest so far has been focused on LA volumetry. And there are very 
few studies investigating the reproducibility of LAA volume measurements, despite heightened 
interest in LAA volumes (369). Previous studies have also indicated that there is a poor correla-
tion between LAA and LA volume, emphasizing the importance of separate LA and LAA evalua-
tions (379, 397, 398). In a previous retrospective study of 74 patients undergoing 64-slice cCT, the 
end-diastolic volume measurements showed significant reproducibility when evaluated with the 
Pearson correlation (388). The different statistical approach complicates the comparison with our 
results. On the other hand, the Bland-Altman plots did not reveal that any significant bias would 
be associated with LA size (388). In another study, 3D threshold-based end-diastolic volume meas-
urements yielded ICC values of 0.961–0.997 for intra-observer and 0.867–0.926 for interobserver 
analyses (389), which are highly compatible with our results. Our current study was carried out 
with relatively old scanners. More novel 320-slice CT scanners visualize the boundaries of the LA 
with more advanced spatial resolution, comparable to 1.5-tesla MRI (390, 412). In a study compar-
ing 320-slice cCT and transthoracic 2D and 3D echocardiography (TTE), the methods showed a 
strong positive correlation, but the absolute value of the LA volume on cCT was significantly larger 
than that determined by either 3D or 2D TTE, which can be due to an overestimation by cCT, an 
underestimation by TTE, or both (413). LAA morphology is widely used for the pre-evaluation 
of percutaneous LAA closure procedures (414).  The main exclusion criterion for this treatment 
is the presence of thrombus in the LAA (415). TEE provides a more comprehensive tool to assess 
decreased blood flow velocity in LAA (408). Nevertheless, detecting solid LAA thrombi seems fea-
sible also with cCT (23). According to our results, LAA volume measurements from different ori-
entations in cCT are comparable. Although reproducible, manual LAA volume measurements are 
highly time-consuming, resulting in a need to develop automatized segmentation tools for clinical 
use. Our results indicate that an automatized segmentation tool may be based on the transversal 
images provided automatically by the CT scan and that no specific stacks need to be formed for 
segmentation. LAA volumes in the 2CV seem to vary only slightly more between different readers.
Our results yielded only slight to fair reproducibility for the visual classification of the morpho-
logical features of the LAA. This result differs from the highly reproducible interobserver assess-
ments of the morphology described by Di Biase et al (374). These workers found no significant bias 
in classifying LAA morphology on CT (ĸ=0.84).  The classification method in Kimura et al (365) 
resulted in an even higher interobserver agreement (ĸ=0.901). Nevertheless, similar to our results, 
Khurram et al (411) reported fair interobserver reproducibility (ĸ=0.427).  Despite excellent tissue 
contrast in cCT, the more complex morphological assessments of LAA are challenging and would 
benefit from supporting quantitative tools or consensus readings between several specialists.
Because stroke recurrence most probably occurs during the first hours or days after the index 
stroke, it is important to determine the stroke etiology as soon as possible if one wishes to prevent 
stroke recurrence. Compared to MRI, cCT is a faster and more widely available imaging modality 
with lower cost (373, 409). The radiological examination of an acute stroke patient usually includes 
not only CT of the brain, but also carotid artery CT angiography combined with imaging of the 
aortic arch (401). Current prospective ECG-gated CT scans allow extremely low radiation doses 
(409). Thus, by extending the scanned area from the carotid arteries and aortic arch down to the 
level of the LAA would not significantly increase the radiation dose, but it could well represent a 
valid method for evaluating the LAA in acute stroke patients (343). While the main indication for 
the cCT in these patients would be the detection or exclusion of LAA or other intracardiac thrombi, 
volumetric and morphological LAA assessments could provide additional information to be used 
in risk stratifications of stroke recurrence (404).
Our study has several limitations. First, our imaging machinery was relatively old and repre-
sented different generations due to the long duration of patient collection. Therefore, the analysed 
data does not represent the cCT quality of the most modern medical care units. However, the repro-
ducibility of volume measurements was excellent and we can assume that more modern scanners 
would yield even better results. Second, neither the morphological assessments nor volumetric 
measurements were performed by experienced cardioradiologists, but by radiology residents or 
research-oriented medical students who were instructed by experts. Therefore, our study shows 
that LAA and LA volume measurements are robust and reproducible even in inexperienced hands, 
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but assessments of morphological type were more challenging and provided only fair reproducibil-
ity at least when conducted by clinically inexperienced observers. On the other hand, the morpho-
logical assessment of LAA is not a routine clinical procedure, and we assume that the use of more 
experienced readers would not have changed the results significantly. Third, intra-observer repro-
ducibility was not analysed in the LAA morphology assessments. Fourth, reproducibility analyses 
should be based on data both from symptomatic patients with a wide range of LAA volumes and 
morphological features, similar to the daily evaluation procedures encountered in clinical practice, 
and a healthy normal population where there would be less differences in the assessed variable. 
Since our study increased the radiation exposure we could not justify its extension to healthy in-
dividuals.
In conclusion, LAA and LA volume measurements with cCT are robust and highly reproducible 
despite differing image qualities, variation in LAA or LA volumes, and measurements in differing 
orientations. The visual assessment of LAA morphology displayed only a fair agreement between 
readers and would benefit from the development of supporting quantitative tools or consensus 
readings between several specialists.
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5 Left atrial appendage volume increased in more 
than half of patients with cryptogenic stroke
 
5.1 ABSTRACT
5.1.1 Background
Ischemic strokes without a well-defined etiology are labeled as cryptogenic, and account for 30–
40% of strokes in stroke registries. The left atrial appendage (LAA) is the most typical origin for int-
racardiac thrombus formation when associated with atrial fibrillation. Here, we examined whether 
an increased LAA volume detected with cardiac computed tomography (cCT) would constitute a 
risk factor in cryptogenic stroke patients.
5.1.2 Methods
This study included 82 stroke/TIA patients (57 males; mean age, 58 years) with a diagnosis of cryp-
togenic stroke after extensive radiological and cardiological investigations. Cases were classified 
using the TOAST criteria modified according to European Association of Echocardiography rec-
ommendations for defining cardiac sources of embolism. Forty age- and gender-matched control 
subjects without cardiovascular diseases were selected for pair-wise comparisons (21 males; mean 
age, 54 years). LAA volume adjusted for body surface area was measured three dimensionally by 
tracing the LAA borders on electrocardiogram-gated CT slices. 
5.1.3 Results
In control subjects, mean LAA volume was 3.4±1.1 mL/m2. Mean+2SD, which was considered the 
upper limit for normal LAA volume was 5.6 mL/m2. In a comparison between the patient group 
and matched controls, LAA volume was 67% larger in cryptogenic stroke/TIA patients (5.7±2.0 mL/
m2 vs. 3.4±1.1 mL/m2; Student T-test P<0.001). Forty-five (55%) patients with cryptogenic stroke/
TIA had enlarged LAA.
5.1.4 Conclusion
LAA is significantly enlarged in more than half of patients with cryptogenic stroke/TIA. LAA 
thrombosis may contribute to the pathogenesis of stroke in patients considered to have cryptogenic 
stroke after conventional evaluation. 
5.2 INTRODUCTION
Stroke is the leading cause of long-term disability, and a major consumer of health-care resources 
worldwide (416). It causes 10% of all deaths and is the second highest cause of mortality (416, 417).
The currently recognized ischemic stroke mechanisms are embolism, decreased perfusion, and 
thrombosis (418). Embolism to the brain can be arterial or cardiac in its origin, with atrial fibrilla-
tion (AF) being by far the most common cause of cardioembolic stroke (419, 420). Ischemic strokes 
without a well-defined etiology are labeled as cryptogenic, and account for 30–40% of all ischemic 
strokes (127). It has been suggested that cardiac embolism may also constitute a major mechanism 
for cryptogenic stroke (131, 403). In a recent multicenter study, outpatient cardiac telemetry for 
over 21 days detected occult paroxysmal atrial fibrillation (PAF) in almost 20% of patients with 
cryptogenic cerebral ischemia (197).
Most cardiac thrombi originate from the left atrial appendage (LAA) (402). An enlarged LAA 
may predispose to blood coagulation due to slow flow velocity (421). The MRI results have shown 
enlarged LAA in stroke/TIA patients with AF (374-376). Moreover, enlarged left atrium (LA) and 
LAA could indicate a propensity for PAF, regardless of sinus rhythm at the time of ischemic epi-
sode (422). The present study aimed to assess whether LAA and/or LA volume is increased in 
patients with cryptogenic stroke/TIA.
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5.3 METHODS
The study was approved by the University Hospital Research Ethics Board. Prior to participation in 
the study, written informed consent was obtained from the patient or the patient’s legally author-
ized representative.
5.3.1 Study design and population
Patients with acute stroke/TIA who were admitted to our university hospital were evaluated as can-
didates for this cardiac CT (cCT) study, EMBODETECT (Figure 10) (343). The neurologists involved 
in this study recruited 162 patients with stroke/TIA of undetermined etiology or with suspected 
cardioembolic etiology other than atrial fibrillation, based on the characteristic clinical symptoms 
and/or primary clinical signs, i.e., simultaneous or sequential strokes/TIAs in different arterial terri-
tories, hemorrhagic transformation, simultaneous emboli in other organs, decreased consciousness 
at stroke/TIA onset, isolated aphasia, or an isolated visual-field defect. Patients with AF recorded 
in their patient file or during time of enrolment were excluded.
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Figure 10. Flow chart of patient recruitment. Neurologists 
recruited consecutive patients with acute ischemic stroke/
TIA with undetermined etiology or a suspicion of cardiogen-
ic etiology. Stroke/TIA patients with atrial fibrillation were 
excluded. Thirteen patients were excluded from the study 
after recruitment. The remaining patients were subjected 
to thorough clinical, cardiological and radiological examina-
tions. Patients were further categorized according to the 
TOAST classification, denoting five subtypes of ischemic 
stroke: 1) large-artery atherosclerosis, 2) cardioembolism, 
3) small-vessel occlusion, 4) stroke of other determined 
etiology, and 5) stroke of undetermined etiology. The clas-
sification was updated by applying the more recent EAE 
recommendations for defining cardiac sources of embolism.
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Of the 162 patients initially recruited, 13 were excluded; the cCT image quality was not ap-
propriate for LAA size analyses in four patients, ECG-synchronization was not used for cardiac 
imaging in three patients, contrast media injection failed in two patients, use of contrast media 
was contraindicated due to an increased serum creatinine level in one patient, and three patients 
refused to participate after giving informed consent.
Transthoracic (TTE) and transesophageal echocardiography (TEE) were performed with the 
Vivid 7 cardiovascular ultrasound system (M4S 3 MHz probe for transthoracic and 6T multiplane 
probe for transesophageal echocardiography; GE Medical Systems, Buckinghamshire, UK), by sev-
eral cardiologists as part of their clinical routine. Contrast-enhanced cardiac MRI (0.2 mmol/kg 
Dotarem; Guerbet, Paris, France) was performed using a 1.5T scanner and 12-element phased-array 
surface coil (Siemens Avanto, Erlangen, Germany), to confirm suspected structural abnormalities in 
cCT (n=18) or in patients with discrepant findings in cCT and echocardiography (n=12). Imaging se-
quences and orientations were planned according to the protocols of the Society of Cardiovascular 
Magnetic Resonance for left ventricle (LV) structure, function, and late gadolinium enhancement 
modules. Ambulatory 24-hour Holter ECG was performed to exclude PAF.
After profound investigations, patients with a defined etiology for stroke (n=67) were further ex-
cluded. Large-artery atherosclerosis was found in 15 patients (10%); cardioembolism in 33 patients 
(22%), including 20 patients (12% of the 162 study patients) having PAF in a 24-hour Holter ambu-
latory ECG recording; small-vessel occlusion in 11 patients (7%); and stroke of other determined 
etiology in 8 patients (5%). We modified the TOAST classification for cardioembolism, applying 
the more recent European Association of Echocardiography (EAE) recommendations for defining 
cardiac sources of embolism (53, 63). The remaining 82 patients (57 males; mean age 58±10 years, 
range 32–82) were considered to have had an acute stroke/TIA of cryptogenic etiology.
5.3.2 Control subjects
Between December 2008 and July 2011, 243 consecutive patients underwent coronary CT-angiogra-
phy (coronary CTA) for exclusion of coronary artery disease. We excluded subjects with coronary 
stenosis of ≥50%, AF, hypertension, renal insufficiency, malignancies, or any neurological diag-
nosis including any symptoms indicative of stroke or TIA —leaving 124 suitable candidates for 
pair-wise comparisons. No additional imaging such as head CT, cervicocranial CT angiography or 
MRI were performed for control subjects. Forty of these patients (21 males; mean age 54±9 years, 
range 32–74) were used as controls to create age- and gender-matched pairs with patients with 
cryptogenic stroke/TIA.
5.3.3 Assessment of LAA and LA size
5.3.3.1 CT imaging
Contrast-enhanced cCT was performed with a 16- (113 patients) or 64-slice (36 patients, 40 control 
subjects) scanner (Somatom Sensation 16 and Somatom Definition AS; Siemens Medical Solutions, 
Forchheim, Germany). Control subjects with initial heart rates higher than 65 beats per minute 
received 5–20 mg metoprolol intravenously before examination. In stroke patients, the aortic arch 
and cervical and intracranial arteries were scanned first, immediately followed by scanning of the 
ascending aorta and heart. When using the 16-slice scanner, contrast agent was injected through 
an 18-gauge catheter into the antecubital vein at 5 mL/s, followed by a 50-mL injection at 2 mL/s 
and a subsequent 20-mL saline chaser. With the 64-slice scanner, 100 mL of contrast agent (350 mg/
mL) was injected at 5 mL/s, followed by a 20-mL injection at 2 mL/s and a subsequent 20-mL saline 
chaser. In coronary CTA, 80 mL of contrast agent (350 mg/mL) was injected at 5 mL/s, followed by 
an 80-mL saline chaser at 5 mL/s. Cardiac imaging was performed during mid-diastole in all study 
subjects. In the 16-slice scanner, collimation was 16×0.75 mm, rotation time was 0.42 s, and tube 
potential was 120 kV; the current was set to 500 mAs for the first 80 patients and reduced to 250 
mAs thereafter. In the 64-slice scanner, collimation was 64×0.6 mm, rotation time 0.33 s, and tube 
potential 120 kV; the reference current was set using commercially available tube current modula-
tion software (CAREDose4D, Siemens Medical Solutions), at 160 mAs for the first 15 patients and 
then reduced to 100 mAs. In coronary CTA, the corresponding values were 64×0.75 mm, 0.17 s, 120 
kV, and 327 mAs, respectively. We calculated the product of CTDIvol and scanning length (dose-
length product in milligrays times centimeters), and estimated the effective dose (in millisieverts) 
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using a normalization factor for the adult chest (0.017 mSv•mGy−1•cm−1). The radiation dose per 
patient was 10.0±3.5 mSv in patients with stroke and 7.9±2.3 mSv in patients with coronary CTA. 
Mid-diastolic 0.75- to 1.0-mm-thick slices with 20–25% overlap were reconstructed. We also recon-
structed 3-mm-thick transversal slices without any gaps or overlap for quantitative measurements.
5.3.3.2 Volumetric analysis of LAA and LA 
Quantitative image analysis was performed on an IDS5 diagnostic workstation (version 10.2P4; 
Sectra Imtec, Linköping, Sweden) using magnified images on 1024×768 and 1600×1200 displays. 
Due to contrast agent injection, the LAA was seen as a hyperdense structure surrounded by hy-
podense pericardial fat, with high tissue contrast between the anatomical structures. The entire 
LAA was fully opacified with contrast media in all study subjects. A two-chamber view and local-
izer tool were used to differentiate the LAA orifice from the LA. The LAA borders were traced 
manually on the transversal slices. LAA trabeculations were considered to be part of the LAA cav-
ity. LA borders were traced from the two-chamber plane using the mitral valve annulus as the land-
mark differentiating the LA from the LV. Planimetration of the LAA totally covered 10.4±2.0 slices 
in the transversal plane, and planimetration of the LA covered 20.0±3.2 slices in the two-chamber 
plane. LAA volume was calculated with Simpson’s method by multiplying each manually traced 
LAA and LA area by the section thickness (3 mm) and summing up the volumes of the separate 
sections (423). Volumes of LAA and LA are presented as unadjusted, and adjusted for height and 
body surface area (BSA). In the definition of the BSA-adjusted LAA volume, BSA was calculated 
using Mosteller’s formula (424). Image analysis was performed by an independent observer (M.T.), 
in the guidance of a radiologist with 15 years of experience with cardiac imaging (P.S.). In the cal-
culation of intraobserver variability, Observer 1 (blind to previous measurements) reconstructed 
new slices and repeated the LAA and LA measurements of 40 patients one month later. Whereas 
interobserver variability, was estimated when Observer 2 reconstructed new slices and analyzed 
LAA and LA volumes from the same 40 patients.
5.3.3.3 Statistical analyses
Continuous variables with normal distribution are presented as mean±SD, and categorical vari-
ables as absolute values and percentages. An enlarged LAA was defined as one with a volume 
exceeding the mean volume in the control population by at least two SD. Based on the presence of 
normal distribution in Kolmogorov-Smirnov test, Student’s T-test was used to compare differences 
in LAA volumes between stroke/TIA patients and control subjects. Analysis of covariance (ANCO-
VA) was used to control for the effects of BMI and hypertension when comparing the LAA and LA 
sizes between stroke/TIA patients and control subjects. Pearson’s correlation coefficient was used to 
investigate the associations between continuous variables, and chi-square test to investigate nomi-
nal variables. Statistical significance was set at P<0.05 and high statistical significance at P<0.01. The 
significance of differences in the proportions of enlarged LAAs and enlarged LAs among stroke/
TIA patients was tested using the McNemar test of proportions. Cohen’s kappa coefficient was 
used to measure dependence of the LAA enlargement on the LA enlargement; kappa values >0.75 
were categorized as high dependence, 0.40–0.75 as moderate dependence, and <0.40 as minor de-
pendence. Intraclass correlation of coefficients (ICC) and coefficients of variabilities (CV%) were 
calculated to assess the reproducibility of LAA and LA measurements. Data were analyzed using 
SPSS for Windows (version 19, 1989–2010 SPSS Inc., Chicago, USA).
5.4 RESULTS
5.4.1 LAA and LA volume in matched patients with cryptogenic stroke/TIA and control subjects
Table 7 shows the clinical characteristics of patients with cryptogenic stroke/TIA and the age- and 
gender-matched control subjects. Stroke/TIA patients were significantly more obese and had larger 
BSA. There were no hypertensive patients in the control group whereas 51% of the patients with 
stroke/TIA suffered from hypertension. Table 8 shows the unadjusted, height-adjusted, and BSA-
adjusted LAA and LA volumes between age- and gender-matched pairs. The LAA volume was 
significantly higher in patients with cryptogenic stroke/TIA (5.7±2.0 mL/m2) than in control subjects 
(3.4±1.1 mL/m2; P<0.001) (Figure 11). LA volume was also significantly higher in stroke/TIA pa-
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tients (43.9±10.9 mL/m2) than in control subjects (32.2±6.7 mL/m2; P<0.001). Accordingly, LAA was 
67% larger and LA 36% larger in patients with cryptogenic stroke/TIA than in control subjects. The 
differences in LAA and LA volumes between the stroke/TIA patients and control subjects remained 
highly significant (P<0.001) when adjusted for BMI and hypertension, together or separately (Table 
8). LAA or LA volumes did not significantly differ between hypertensive (n=16) and normotensive 
(n=24) nor between obese (n=15) and non-obese (n=25) stroke/TIA patients. 
Figure 11. Left atrial appendage (LAA) volumes (mL/m2) in 40 cryptogenic stroke/TIA patients (squares/circles) 
and 40 age- and gender-matched control subjects (triangles), with 95% confidence interval. Mean LAA volume 
(5.7±2.0 mL/m2) was 67% higher in matched patients with stroke/TIA than in control subjects (3.4±1.1 mL/
m2). Volume enlargement was similar between stroke patients (squares) and TIA patients (circles), and between 
hypertensive (black) and normotensive (white) patients.
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Age, yr
ns.
0.002
0.033
Caucasian race, n (%) ns.
<0.001
ns.
ns.
Table 7. Clinical characteristics of 40 patients with acute cryptogenic stroke/TIA and 40 age- and gender-matched control 
subjects
ns.
P
ns.
ns.
Hyperlipidemia, n (%)
Diabetes, n (%)
Left ventricle ejection fraction, %
Characteristic
Males, n (%)
Body mass index, kg/m2
Body surface area, m2
Hypertension, n (%)
Smokers, n (%)
Left ventricle dysfunction, n (%)
ns.
Stroke/TIA Patients
21 (52.5)
25.3±4.1
1.8±0.2
40 (100.0)
0 (0)
16 (40.0)
0 (0.0)
53.8±9.0
Control Subjects
21 (52.5)
28.7±4.8
2.0±0.2
40 (100.0)
16 (40.0)
14 (35.0)
0 (0.0)
53.9±9.3
0 (0.0)
66.0±10.2
0 (0.0)
63.7±7.7
1 (2.5)0 (0)
Table 8. Left atrial appendage (LAA) and left atrium (LA) volume measurements, pair-wise comparison between patients with cryptogenic stroke 
(n=40) and age- and gender-matched control subjects (n=40)
Significance
Stroke patients (n=40)
Control subjects (n=40)
ANCOVA*
11.1±3.8 mL
6.2±1.9 mL
<0.001
<0.001
LAA mean volume
85.5±21.1 mL 
59.8±15.3 mL
<0.001
<0.001
LA mean volume
6.5±2.2 mL/m
3.7±1.1 mL/m
<0.001
<0.001
LAA mean volume
50.5±12.6 mL/m 
35.1±8.0 mL/m 
<0.001
<0.001
LA mean volume
5.7±2.0 mL/m2
3.4±1.1 mL/m2
<0.001
<0.001
LAA mean volume
43.9±10.9 mL/m2
32.2±6.7 mL/m2
<0.001
<0.001
LA mean volume
Unadjusted Height Adjusted Body Surface Area Adjusted
TIA, transient ischemic attack; yr, year
*Adjusted for BMI and hypertension
Based on the volume measurements conducted in the control subject population, the upper 
thresholds for normal LAA volume were 10.1 mL (unadjusted), 5.9 mL/m (height adjusted), and 
5.6 mL/m2 (BSA adjusted). The upper thresholds for normal LA volume were 90.4 mL, 51.1 mL/m, 
and 45.6 mL/m2, respectively. LAA volume was over 5.6 mL/m2 in 23 (58%) of the 40 patients with 
cryptogenic stroke/TIA, but in only two (5%) of the control subjects (P<0.001). LA volume was over 
45.6 mL/m2 in 20 (50%) patients with cryptogenic stroke/TIA, but in only one (3%) control subject 
(P<0.001).
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57 (69.5)
28.2±4.3
2.0±0.2
82 (100.0)
42 (51.2)
27 (32.9)
7 (8.5)
Table 9. Clinical characteristics of 82 patients with acute cryptogenic stroke/TIA
57.8±10.5
11 (13.4)
21 (25.6)
Characteristic
Cholesterol, mg/dL*
2 (2.4)
Age, yr
Caucasian race, n (%)
Hyperlipidemia, n (%)
Diabetes, n (%)
Smokers, n (%)
Males, n (%)
Body mass index, kg/m2
Body surface area, m2
Hypertension, n (%)
Prior myocardial infarction, n (%)
Warfarin
Clopidogrel
Dipyridamole
Aspirin
Prior stroke, n (%)
Medication, n (%) 16 (19.5)
4 (4.9)
2 (2.4)
2 (2.4)
108.3±37.1
16 (19.5)
46.4±19.7
Low-density lipoprotein
High-density lipoprotein
Statin
*Data missing for one patient
5.4.2 LAA and LA volume in patients with cryptogenic stroke/TIA
Table 9 summarizes the clinical characteristics of all 82 patients with cryptogenic stroke/TIA. Forty-
five patients (55%) had an enlarged LAA and 39 (48%) had an enlarged LA using BSA-adjusted 
threshold values. Both LAA and LA were enlarged in 27 patients, 18 patients had normal LA volume 
despite an enlarged LAA, and 12 patients had an enlarged LA volume but normal LAA volume. 
Cohen’s kappa coefficient indicated minor association (P=0.272) between LAA and LA enlarge-
ment, and the McNemar test showed this association to be statistically nonsignificant (P=0.362).
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5.4.3 Reproducibility of volume measurements
In the volume reproducibility measurements, we found no significant interobserver difference in 
LAA (5.0±2.4 mL/m2 vs. 5.7±2.5 mL/m2, P=0.240) or LA volumes (42.2±13.9 mL/m2 vs. 44.7±14.5 
mL/m2, P=0.440). Nor did we find significant intraobserver differences in LAA (5.0±2.4 mL/m2 vs. 
4.7±2.2 mL/m2, P=0.544) or LA volumes (42.2±13.9 mL/m2 vs. 42.1±14.1 mL/m2, P=0.976). The intra- 
and interobserver CV% values were 12.6% and 11.2% for LAA, respectively, and 4.6% and 10.0% 
for LA. The corresponding ICCs were 0.95 and 0.96 for LAA, respectively, and 0.99 and 0.95 for LA.
5.5 DISCUSSION
The main finding of the current study was that more than half (55%) of the consecutive patients 
with cryptogenic stroke/TIA had an enlarged LAA. In general, the LAA volume was 67% larger in 
patients with cryptogenic stroke/TIA when compared to age- and gender-matched control subjects. 
This result remained unchanged in the subgroup analyses with normotensive or non-obese study 
patients. Interestingly, the observed LAA enlargement was more pronounced than the LA enlarge-
ment (67% vs. 36%) and thus it may be more sensitive than an LA measurement for detecting a 
diseased LA-LAA system. A 24-hour Holter assessment has only a marginal ability to exclude the 
propensity for PAF; therefore, our study patients with stroke/TIA may actually suffer from asymp-
tomatic PAF (192, 199).
We are not aware of any previous studies investigating LAA volumes in patients with cryp-
togenic stroke/TIA, or any stroke/TIA patients without AF. It has previously been suggested that 
measurement of LAA volume could theoretically be valuable for detecting at risk patients, because 
cardioembolic stroke/TIA is a common source of ischemic stroke/TIA, and over 90% of detected LA 
thrombi are found within the LAA (151, 419).LAA enlargement is known to play a part in thrombus 
formation, independently as well as in association with decreased LAA contraction (402), and there 
is evidence emerging that specific LAA morphology more frequently indicates thrombus formation 
(394).
Study subjects were scanned at mid-diastole which provides the most constant image quality in 
terms of minimal motion artefacts (425). We found that normal LAA mean mid-diastolic volume 
to be 6.2±1.9 mL (unadjusted), 3.7±1.1 mL/m (height adjusted), and 3.4±1.1 mL/m2 (BSA adjusted). 
In a previous cCT studies by Lacomis et al (372), the normal LAA mean volume was 6 mL (range 
5–13 mL) at mid-diastole and according to Christiaens et al (370), the normal LAA mean maximal 
volume measured at end-systole was 9±3 mL, and normal LAA mean minimal volume measured 
in end-diastole was 4±2 mL. The study of Nedios et al, reported that normal maximal LAA volume 
at end-systole was 6.5±1.9 mL (381). When referred to 143 necropsy LAA casts (4.6 mL) of patients 
with sinus rhythm, we obtained slightly larger volumes. Necropsy LAA volumes from patients 
who suffered from FA or cardioembolism were larger than in our control subjects (363). Altogether, 
our results are in parallel these values, althought one must recognized that the scanning phase in 
our study was between LAA maximal (end-systole) and minimal (end-diastole) volume. 
We found that there was a narrow range of normal LAA mid-diastolic volumes. The cut-off for 
normality at the 5.6 mL/m2 was exceeded in two control subjects, but in 23 (58%) age- and gender-
matched patients with cryptogenic stroke/TIA. This enlargement was not accounted for by any pre-
viously recognized factors causing LA-LAA-system dilatation, such as mitral valve insufficiency or 
LV dysfunction, because our study groups did not display these conditions. The results could also 
not be explained by arterial hypertension or obesity, as the difference remained unchanged when 
the volumes were adjusted for these variants and when the analyses were performed in subgroups 
without hypertension or obesity. 
Recently, a TEE study utilizing a 3D approach, a MRI study and three CT-based studies reported 
increased LAA volumes in patients with PAF (13 mL, range 6–51 mL; 8.1±5.1 mL; 10.6±4.1 mL; 
8.1±2.5 mL), and even higher LAA volumes in patients with persistent AF (10.5±5.9 mL; 16.5±7.1 
mL; 10±5.1 mL) (367, 372, 379, 381, 382). These findings have been verified by MRI studies in pa-
tients with persistent AF and PAF (376, 382, 394). Interestingly, our study patients with cryptogenic 
stroke/TIA had LAA volumes (11.1±3.8 mL) almost as large as the patients with PAF in those stud-
ies (13.0±6.1 mL), while the LAA volumes in patients with persistent AF were substantially higher 
(14.3±6.2 mL; 15.04±07.1 mL; 17.3±6.7 mL). In previous cCT studies by Whisenant et al, both groups 
52
suffering from AF with (28.8±13.5 mL) and without (21.7±8.3 mL) stroke/TIA history, had much 
larger LAA mean volumes compared to our cryptogenic stroke/TIA patients (373).
Studies investigating LA volume in patients with cryptogenic stroke/TIA are scarce. LA dilata-
tion has been previously found in only 6.7% of stroke/TIA patients (334), but contradictory results 
have also been reported (151). Both studies utilized the LA diameter to determine LA enlargement. 
It seems likely that three-dimensional volume measurements provide more accurate results and 
narrower limits for normality, due to their higher measurement accuracy (23, 387).
There is evidence that cardiac embolism represents a major mechanism for cryptogenic stroke 
(131, 403, 426). Manina et al (132) found that AF may be detected in over 24% of patients assumed 
to have cryptogenic stroke/TIA using long-term ECG registrations. In another recent study, PAF in 
episodes from 5–30 seconds was found in 10% of patients with cryptogenic stroke. However, the 
significance of very short-term (<30 sec) PAF-bursts in patients with cryptogenic stroke is unknown 
because these kind of arrhythmias have also been found to be common in healthy individuals (193, 
200, 427, 428). Our findings raise the possibility that LAA/LA volumetry could improve cardioem-
bolic profile characterization in patients with short-term AF bursts.
The study population included patients with stroke/TIA of undetermined origin or with a clini-
cal suspicion of cardioembolic origin, which may overemphasize the finding of enlarged LAA com-
pared to all patients with cryptogenic stroke. On the other hand, the suspicion of cardioembolic 
stroke/TIA was based on nonspecific symptoms that are common in all stroke/TIA patients, and/or 
the absence of significant carotid disease, which is also frequently encountered in clinical routine. 
Accordingly, these study subjects represent the typical patients with cryptogenic stroke. The main 
study limitation was that the number of patients in our study was relatively small and that our 
study protocol did not include follow-up of the patients which would have detected any increased 
risk for atrial arrhythmias, thrombi or recurrent stroke. Despite all our efforts and extensive brief-
ing of neurologists, a substantial number of stroke/TIA patients were not screened here due to 
heavy clinical work load.
In conclusion, we found that LAA was enlarged in more than half of patients with cryptogenic 
stroke/TIA. The assessment of LAA and LA volumes may be valuable in the etiological work-up 
of stroke/TIA without any defined etiology. Based on the measurements in the control population, 
a mid-diastolic LAA volume larger than 5.6 mL/m2 is indicative of LAA enlargement. Currently, 
further examination for asymptomatic AF of patients with an enlarged LAA in cCT may be recom-
mended, since AF as an etiology for stroke/TIA may significantly affect the treatment selection of 
these patients.
53
6 Determinants of left atrial appendage volume 
in stroke patients without chronic atrial fibrilla-
tion
 
6.1 ABSTRACT
6.1.1 Background
Left atrial appendage (LAA) volume has been shown to be increased in patients with acute cryp-
togenic stroke. Atrial fibrillation (AF) is a well-recognized but not only risk factor associated with 
LAA enlargement. The aim of the study was to clarify the multifactoral etiology of LAA enlarge-
ment in cardiogenic stroke/TIA patients without AF.
6.1.2 Methods
Altogether 149 patients with suspected cardioembolic stroke/TIA (47 females; mean age 61 years) 
underwent cardiac CT. Diagnosed AF on admittance was an exclusion criteria but 24-hour Holter 
ambulatory ECG revealed paroxysmal AF (PAF) in 20 patients. Body surface area adjusted LAA 
volume was evaluated. Eighteen different variables were registered including general character-
istics, definite and potential causal risk factors for ischemic stroke/TIA, clinical echoparameters 
and CT based cardiac volumetric and adipose tissue measurements. A stepwise linear regression 
analysis was performed to achieve a model adjusted for the number of predictors of the increase 
in the LAA volume. 
6.1.3 Results
In linear regression analysis, the best model accounted for 30% of the variability in LAA volume, in-
cluding PAF (19%) and enlarged left atrial volume (6%), enlarged left ventricle end-systolic diame-
ter (3%) and decreased pericardial adipose tissue (2%). No multi-colinearity was observed between 
variables. In addition to PAF, no other definitive or potential causal risk factors could account for 
the LAA volume in these patients.
6.1.4 Conclusions
LAA volume increase seems to be poorly associated with currently known stroke/TIA risk factors, 
except for AF. Targeting more comprehensive ECG monitoring for stroke patients with increased 
LAA volume should be considered.
6.2 INTRODUCTION
Despite improvements in stroke mortality in Western societies, stroke remains the second leading 
cause of death worldwide (400). The presence of an embolus in the brain is a well-recognized etiol-
ogy for ischemic stroke together with decreased perfusion and thrombosis (53). It has been sug-
gested that cardioembolism may constitute a major mechanism not only for cardiogenic but also 
for cryptogenic stroke (131, 404, 429). When derived from the heart, an embolus may be induced 
by either chronic atrial fibrillation (AF) or paroxysmal atrial fibrillation (PAF) via predisposing clot 
formation and by reshaping of the left ventricle (LV), left atrium (LA), and left atrial appendage 
(LAA) (375, 421, 430). Over 90% of all cardioemboli are formed in the LAA (421).  The LAA has been 
shown to be frequently enlarged in patients with acute cryptogenic stroke or a transient ischemia 
attack (TIA) (404). Both AF and PAF are known to contribute to LAA enlargement (367, 398).  How-
ever, the factors associated with LAA volume increase are not fully understood.
Improvements could be achieved in the risk stratification of stroke recurrence and the provision 
of appropriate anticoagulation, or other treatment targeting, if there was a more comprehensive 
understanding of stroke pathogenesis. In the current study we measured LAA volumes with car-
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diac CT (cCT) and adjusted the volumes for patient’s body surface area (BSA) (424). Our aim was to 
identify the clinical factors and/or imaging findings that are associated with LAA volume increase. 
6.3 METHODS
The EMBODETECT study was approved by the local research ethics board. Prior to participation, 
written informed consent was obtained from the patient or the patient’s legally authorized repre-
sentative if the patient was unable to give consent due to impaired capacity caused by stroke or 
TIA.
6.3.1 Study design and patients
Between March 2005 and November 2009, our neurologists recruited 162 patients who had been 
admitted to Kuopio University Hospital with suspected cardioembolic stroke/TIA. Patients whose 
symptoms were not explained by a hemodynamically significant (>50%) carotid/vertebral artery 
stenosis, or by AF diagnosed previously (or during hospitalization), were considered ase eligible to 
enter the study. Thirteen patients were excluded due to technical errors or because they refused to 
participate having previously given informed consent. Altogether 149 patients (47 females; mean 
age 61 years; range 32–84 years) with suspected cardioembolic stroke/TIA underwent CT-angi-
ography performed with ECG-synchronized mid-diastole cCT (16- or 64-slice, 120 kV, 190 mAs), 
enabling cardiac volumetric analyses. Transthoracic echocardiography (TTE) and 24-hour Holter 
ambulatory ECG were performed (343). The proportions of visceral (VAT), intrathoracic (IAT) and 
pericardial (PAT) adipose tissue were measured.
6.3.2 Determinants for LAA volume
Study patients were dichotomized into subgroups according to their general characteristics and 
many other variables. These included the presence of defined (hypertension (431), dyslipidemia 
(432), carotid stenosis (433, 434), and PAF (435)) and potential (smoking (436), diabetes (431), prior 
ischemic heart disease (437), and mitral valve insufficiency (438, 439)) causal risk factors for ischem-
ic stroke, cardiac echoparameters, cCT based volume measurements, and adipose tissue measure-
ments (Figure 12).
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For dichotomization of mitral valve insufficiency, grade II mitral regurgitation was used as a 
threshold. Dimensions in echo parameters and ejection fraction were dichotomized by the guide-
lines of the American Society of Echocardiography (ASE) (440). To derive upper thresholds for cCT 
based measurements, 243 consecutive patients who underwent coronary CT-angiography (coro-
nary CTA) to exclude coronary stenosis were evaluated as candidates for healthy controls. Subjects 
with coronary stenosis of >50%, AF, hypertension, renal insufficiency, prior stroke or malignancies 
were excluded, which left 40 patients available to create age- and gender-matched pairs with our 
stroke/TIA patients (404). The upper thresholds for normal variances in LAA and LA volume were 
set to two standard deviations above the mean of the control population. Upper thresholds for IAT 
and PAT were based on the same control population. The upper thresholds for VAT (>122.8 cm2 in 
females; >188.4 cm2 in males) were based on results obtained from an ethnically comparable North 
American population (n=1160) (441).
6.3.3 Volumetric analysis of the LAA and LA
Quantitative image analysis was performed on an IDS5 diagnostic workstation (version 10.2P4; 
Sectra Imtec, Linköping, Sweden) by an independent observer (MT), guided by an experienced 
cardioradiologist (PS). The volumetric analyses of LAA were performed three-dimensionally using 
the cCT stack. Planimetration of LAA covered 10.4±2.0 consecutive slices in the transversal plane. 
A two-chamber view and a localizer tool were used to differentiate the LAA orifice from the LA. 
The LAA borders were traced manually on each transverse slice while the LA borders were traced 
from the consecutive slices on two-chamber plane using the mitral valve annulus as the landmark 
differentiating the LA from the LV. LAA volume was calculated with Simpson’s method by multi-
plying each manually traced LAA and LA area by the section thickness (3 mm) and summing up 
the volumes of the separate sections (423). Volumes of the LAA are presented with adjustment for 
BSA, which was calculated using Mosteller’s formula (424). In our previous study intra-class corre-
lations (ICC) for the LAA volume measurements resulted in almost perfect reproducibility between 
different observers (ICC=0.96) and the same observer (ICC=0.95) (404).
6.3.4 Measurements of pericardial, intrathoracic and visceral adipose tissue
The PAT area was calculated by drawing a line through the parietal layer of the pericardial sac. 
The IAT area was calculated via the parietal layer of the pleural cavity from sternum to the anterior 
surface of the ascending aorta. The IAT included all PAT. Both measurements were performed from 
a single axial slice (slice thickness 7.5 mm) from the opening level of the common left coronary ar-
tery. The VAT area (slice thickness 10 mm) was calculated by drawing a line within the muscle wall 
that delineated the abdominal cavity at the level of the fourth lumbar vertebra. The adipose tissue 
surfaces were computed with an attenuation range from −30 to −190 Hounsfield Units.
6.3.5 Statistical analyses
Continuous variables with normal distribution are presented as mean±SD, and categorical vari-
ables are presented as absolute values and percentages. Student’s T-test for individual samples 
was used to evaluate the differences in the LAA volumes between dichotomized groups. Inclu-
sion criteria for multifactoral linear regression analyses were set at P<0.2, statistical significance at 
P<0.05 and high statistical significance at P<0.01. In multivariate analysis, tolerance>0.2 was used 
to indicate non-multicolinearity of variables. In the stepwise method, the variables were entered if 
F<0.05 and removed if F>0.1. The change in R2 and adjusted R2 value were used to assess the contri-
bution of each variable to the LAA volume. Data were analyzed using SPSS for Windows (version 
19, 1989–2010 SPSS Inc., Chicago, USA).
6.4 RESULTS
Table 10 shows the clinical characteristics and uncategorized values of echocardiography and CT 
measurements of the patients. Only BSA-adjusted values were used in regression analyses. Thresh-
old values of LA volume, PAT and IAT area were based on the control population. In comparison 
between 40 age- and gender-matched stroke/TIA patients and control subjects, no significant dif-
ference was found in terms of hyperlipidemia, diabetes, EF, LV dysfunction (no identified wall 
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dyskinesia) or smoking. Body mass index (BMI) was 28.7±4.8 kg/m2 in stroke/TIA patients and 
25.3±4.1 kg/m2 (P=0.002) in control subjects. BSA was 2.0±0.2 m2 in stroke/TIA patients and 1.8±0.2 
m2 (P=0.033) in control subjects. All 18 threshold values are shown in Figure 12.
47 (31.5)
28.1±4.4
2.0±0.2
149 (100.0)
88 (59.1)
61 (40.9)
22 (17.8)
Table 10. Clinical characteristics of patients with suspected cardioembolic stroke/TIA
60.9±10.6
19 (12.8)
38 (25.5)
29 (19.5)
Age, yr
Caucasian race, n (%)
Hyperlipidemia, n (%)
Diabetes, n (%)
Smokers, n (%)
Females, n (%)
Body mass index, kg/m2
Body surface area, m2
Hypertension, n (%)
Prior myocardial infarction, n (%)
Grade I mitral regurgitation on TTE, n (%)
Grade II mitral regurgitation on TTE, n (%)
No mitral regurgitation on TTE, n (%)
Prior stroke, n (%)
59 (48.4)
47 (38.5)
15 (10.1)
1 (0.8)
62.6±10.7
39.9±6.8
32.9±7.2
Grade III mitral regurgitation on TTE, n (%)
Left atrium antero-posterior diameter on TTE, mm
Left ventricle ejection fraction, %
Left ventricle end-systolic diameter on TTE, mm
Left ventricle end-diastolic diameter on TTE, mm
Left atrium volume on CT, mL
Left atrium volume on CT adjusted for height, mL/m
Left atrium volume on CT adjusted for BSA, mL/m2
Left atrial appendage volume on CT, mL
Left atrial appendage volume on CT adjusted for height, mL/m
Left atrial appendage volume on CT adjusted for BSA, mL/m2
Pericardial adipose tissue area on CT, cm
Intra-thoracic adipose tissue area on CT, cm2
Visceral adipose tissue area on CT, cm2
149
149
149
149
149
149
149
149
149
149
149
122
122
122
122
146
146
142
142
149
149
149
149
149
149
137
137
111
94.8±32.1
50.5±6.6
55.3±18.1
12.3±5.2
48.4±16.0
7.2±3.0
13.5±7.1
6.3±2.7
29.2±14.1
192.3±92.6
ValueCharacteristic N
TIA, transient ischemic attack; yr, year; TTE, transthoracic echocardiography; BSA, body surface area
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6.4.1 Correlates of LAA volume in linear regression analysis
The possible correlates of LAA volume adjusted for BSA (mL/m2) are shown in Figure 12. In uni-
variate analyses, age, previously diagnosed hypertension, atrial fibrillation seen by 24-hour Hol-
ter ambulatory ECG, diabetes, mitral valve insufficiency, antero-posterior diameter of the LA, EF, 
LVSD and LVDD, LA volume and LV PAT were associated with LAA volume (P<0.2) and were 
included in our multivariate linear regression analyses. No significant multi-colinearity (tolerance 
0.473–0.892) was observed between the variables.
To investigate independent predictors of LAA volume, stepwise linear regression analysis was 
performed. The best model accounted for 33% of the variability in LAA volume, whilst AF ac-
counted for 19% (P<0.001); enlarged LA volume for 7% (P=0.011); enlarged LVSD for 4% (P=0.007) 
and decreased PAT for 3% (P=0.043) of the variability. When adjusted for the number of predictors, 
these variables accounted for 19%, 6%, 3% and 2% of the variability in LAA volume, respectively. 
The whole model accounted for 30% of the LAA volume variability when adjusted for the number 
of predictors.
6.5 DISCUSSION
An enlarged LAA represents an established risk factor for cardioembolic stroke (375). In a recent 
study, over half of all cryptogenic stroke/TIA patients had an enlarged LAA, indicating that cardi-
oembolism may play a role in the mechanism of stroke in these patients (404). Chronic AF and PAF 
are generally considered to be causative factors for secondary LAA enlargement (375). To the best 
of our knowledge, no previous study has examined the factors that correlate with the LAA volume 
increase in patients with stroke/TIA. We found that previously recognized risk factors for ischemic 
stroke/TIA combined with routine echo parameters and more novel CT parameters together ex-
plain only 30% of the LAA volume increase. These factors proved to be AF, enlarged LA volume, 
enlarged LV systolic diameter and decreased pericardial fat. The prevalence of these risk factors 
could naturally explain LAA dilatation and furthermore as reasons for the formation of throm-
bus in the LAA, which contribute to the pathogenic mechanism of cardioembolic stroke/TIA. In 
particular, PAF may easily remain unrecognized in routine clinical evaluation (426). Therefore, in 
patients with stroke/TIA, an assessment of LAA size with cCT might help to identify those patients 
who should be more carefully monitored for possible AF.
Atrial fibrillation explained 19% of the LAA volume variation in the present study. It has been 
suggested that PAF plays a vital role in LAA volume increase even if not diagnosed with current 
methods (426). In our study, AF diagnosis was based on 24-hour Holter ambulatory ECG. It is likely 
that even more PAFs would have been recognized if it had been possible to have more prolonged 
ECG monitoring such as 7-day Holter ambulatory recording or event recording. The volume in-
crement of the LAA due to AF has been verified by MRI studies. Stroke/TIA patients with PAF in 
our study (9.37±3.40 mL/m2 when adjusted for BSA corresponding to 18.74±6.80 mL when non-
adjusted) proved to have even larger LAA volumes compared to patients with PAF (13.0±6.1 mL) 
or chronic AF (14.3±6.2 mL; 15.04±07.1 mL; 17.3±6.7 mL) in those previously published MRI studies 
(376, 382, 394).
Second to AF, LA dilatation had an impact on LAA size, explaining 6% of the volume increase. 
This proportion remains surprisingly small despite the anatomical connection of the structures, 
indicating that the function and factors influencing their size differ. Indeed, the LAA is not only a 
component of the LA but it constitutes a separate chamber of the heart with embryological, ana-
tomical, and functional features distinct from those of the LA (145). On the other hand, LAA en-
largement has been shown to be associated with LA filling pressure and hypertension (442). Since 
it is compliant, the LAA is likely to increase in size prior to the LA volume increase (443, 444). The 
risk of stroke has been suggested to double for every 10 mm increment in LA diameter in males 
(445). Subsequent investigations have confirmed the correlation between stroke/TIA risk and BSA 
adjusted LA volume enlargement (404).
Our results also show that increased LV systolic diameter on TTE, indicating LV dysfunction, 
explains 3% of LAA volume increase. In patients with dilated cardiomyopathy, LV dimensions 
correlate significantly with LAA size (446). Importantly, in those patients, systolic dysfunction was 
associated with a high prevalence of LV (13%) and LAA (96%) thrombus in patients with sinus 
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rhythm (446). These results parallel other studies investigating the relationship between LV systolic 
function and LAA thrombus formation (406, 447, 448). We hypothesize that LV dilation not only 
influences LA dilation and enhances LAA dilation but reduces LAA flow velocity (22). The elevated 
filling pressures in the left ventricle contribute to the deterioration of the LAA flow, which in turn 
increases LAA volume (449).
Interestingly, a low amount of pericardial fat was associated with an increased LAA volume. 
The observed impact was minor and our finding is somewhat controversial in relation to previ-
ously published studies (450, 451). There appears to be a graded relationship between a higher 
pericardial fat burden in chronic AF patients as compared to PAF patients that is independent of 
BMI (452). This may partly explain why a smaller PAT area was found in those patients with higher 
LAA volumes. Patients with chronic AF were excluded from our study while patients with lower 
volumes of PAT may suffer from PAF (426, 453). More prospective studies for the evaluation of 
causalities between LAA volume, arrhythmias and adipose tissue are highly needed. It is notewor-
thy, that PAT showed no statistical significance (P=0.133) in the univariate analysis. No conclusions 
about the role of increased PAT and risk of recurrent stroke can be made from this study.
Our study has some limitations. Firstly, the number of stroke/TIA patients included in the study 
was relatively small. However, patients were randomly selected without any sampling bias. Sec-
ondly, 24-hour ECG monitoring is not able to reveal short-term PAFs with long intervals. There-
fore, it is likely that PAF plays a more prominent role in cardioembolic stroke/TIA pathogenesis 
than is currently known. Thirdly, the definition of hypertension and dyslipidemia were based on 
previously established diagnoses, and no non-diagnosed cases were detected. A diagnosis of hy-
pertension cannot be based on blood pressure measurements in the acute phase of stroke/TIA and 
comprehensive blood lipoprotein assays were not monitored. Stroke/TIA patients had higher BMI 
values and a larger BSA than control subjects. Adjustment of the LAA volume for BSA can only 
decrease the impact of LAA volume increase in stroke/TIA patients compared to controls. This may 
lead to a negative bias in our hypothesis but does not overestimate the final  result. It has also previ-
ously been shown that obesity has no significant impact on these results (404). While BSA is linked 
to patients’ weight and hence, to the amount of adipose tissue, adjusting LAA volume for the BSA 
may interfere in the association of PAT area and LAA volume.
To conclude, the extent of LAA enlargement is poorly linked with causative stroke/TIA risk 
factors and other imaging measurements, implying that it might be a relatively independent patho-
genic mechanism for cardioembolic stroke/TIA. While PAF recorded with 24-hour Holter ambula-
tory ECG explains only 19% of LAA increase, it would be ideal to conduct more extensive ECG 
monitoring in those stroke/TIA patients with large LAA volumes measured by cCT. If an associa-
tion between an enlarged LAA and an increased risk for cardioembolic stroke recurrence can be 
verified in future studies, cCT imaging may help to identify those patients most in need of compre-
hensive ECG monitoring.
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7 General discussion
 
It has been previously shown that LA dilatation is associated with thrombogenesis, evidence that 
LA volume, when corrected for BSA, might be an independent risk factor for stroke (61, 388, 394, 
454-457). Since almost all cardiogenic thrombi are derived from LAA, it would not be a surprise 
that an enlarged LAA would be even more important in the pathogenesis of thrombosis than an 
enlarged LA (21). However, previous studies have detected only a modest correlation between 
LAA and LA volumes underlining the importance of separate LA and LAA evaluation (379, 397, 
398). Indeed, there is evidence that an increased LAA volume has a similar ability to predict stroke 
risk as the clinical measures of CHADS2 score and the expanded CHA2DS2-VASc score (373, 399).
LAA volume is increased in patients with chronic AF (381). In addition, patients with PAF have 
significantly higher LAAs compared to patients with sinus rhythm (377). In the present studies, 
cryptogenic stroke patients proved to have almost as large LAAs as patients with PAF in previous 
studies (364). This raises the question of whether cryptogenic patients who show no signs of AF in 
24-hour ECG Holter may indeed suffer from a rarely manifesting PAF.
The usefulness of imaging data is dependent on the availability of robust and reproducible 
measurements. The LAA volumes in this study were measured with manual planimetration of cCT 
data. The present studies revealed that LAA and LA volume measurements are highly reproducible 
and comparable between observers. The present measurement protocol seems to be very robust i.e. 
variability in image quality or measurement orientation does not have any significant influence on 
the results. In contrast, visual classification of LAA morphology had only fair interobserver repro-
ducibility. However, both of these methods are time-consuming, and automated segmentation will 
be needed before these kinds of measurements will become as a seamless part of clinical routine.
Genetic and epidemiologic studies suggest that cardiac embolism represents the major mecha-
nism for cryptogenic stroke (131, 458, 459). It is currently recommended that cardiac monitoring 
should be performed for at least the first 24 hours after an acute stroke evaluation (188). However, 
the detection rate of AF in 24-hour ECG Holter monitoring is not sufficient and it seems to be infe-
rior to three days’ serial ECG recording (188). The improved technology has made possible to per-
form long-term cardiac rhythm monitoring for up to months or even years after a stroke (197, 201). 
However, even when long ECG registration has been available, AF has been found in 10−24% of 
the patients assumed to have cryptogenic stroke/TIA after the intial evaluation (132, 193). It should 
be noted that the significance of very short-term (<30 sec) PAF-bursts in the pathogenesis of stroke 
in patients with cryptogenic stroke is not clear because these kinds of arrhythmias have also been 
found to be common in healthy individuals (83). In-hospital and outpatient telemonitoring as well 
as implantable loop recorders all seem to be ways to improve the detection to detect AF and are su-
perior to 24-hour ECG Holter monitoring, although there are claims that the  yield varies strongly 
depending on the patient population (190-201, 460). These findings raise the question of whether 
LAA volumetry could improve the characterization of cardioembolic risk profile among patients 
with short-term AF bursts.
It would be tempting to combine CT to the initial evaluation of the acute stroke patient in order 
to obtain an estimate of the risk of recurrent stroke. It has been postulated that the combination of 
ECG-gated cardiac imaging with aortic arch and carotid artery imaging could serve as a ‘one-stop-
shop’ for the etiological assessment of stroke patients with no need for further TEE or TTE. There 
is evidence that there is a good agreement between CT and TEE in the detection of cardiac risk 
sources of embolism in stroke patients (343). If future studies support the use of cardiac CT in acute 
stroke patients, then imaging data could be used not only to detect thrombi, but also to evaluate 
LAA volume (461). This may help to target prolonged rhythm monitoring in the most appropriate 
patients.
To conclude, cCT represents a faster method to evaluate LAA in comparison with TEE. Every 
acute stroke/TIA patient will be subjected to a CT scan for hemorrhage exclusion.  CT also is su-
perior to TEE for detection of atherosclerotic aortic plaques particularly in the important group of 
patients with cryptogenic stroke. TEE is a radiation dose-free method, but it demands good patient 
cooperation, which is not always guaranteed in severely ill stroke/TIA patients. MRI is a slower and 
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more expensive method in comparison to CT and therefore may not be suitable as a fast first line 
decision-making tool, although it has been shown to be capable of detecting LAA thrombi. The new 
3D approach in echocardiography looks promising and may offer good LAA visualization without 
radiation exposure.
There are limitations in the results described in this thesis, i.e. the number of stroke/TIA patients 
included in the study was relatively small. However, it is argued there would be no  sampling 
bias since the patients were randomly selected. Another limitation is the fact that 24-hour ECG 
monitoring is recognized as not beingable to reveal short-term PAFs with long intervals. If more 
prolonged ECG monitoring had been available it would have been possible to detect more patients 
to be categorized into the cardiogenic stroke etiology group. Thirdly, the definitions of hyperten-
sion and dyslipidemia were based on previously established diagnoses, and non-diagnosed cases 
were not correctly categorized. A diagnosis of hypertension cannot be based on blood pressure 
measurements in the acute phase of stroke/TIA and comprehensive blood lipoprotein assays were 
not available. Stroke/TIA patients had higher BMI and larger BSA than control subjects. Adjusting 
for the LAA volume with BSA can only decrease the impact of LAA volume increase in stroke/TIA 
patients as compared to controls. This may lead to a negative bias in the present hypothesis but 
it does not overestimate the result. The equipment used in these tests was also relatively old and 
individual readers performed the volumetric analyses, therefore it will be important to verify these 
results with more modern CT devises incorporating an automatized segmentation tool.
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8 Conclusions
 
LAA and LA volume measurements with cCT are robust and highly reproducible despite differ-
ences in image quality, variations in LAA or LA volume, and measurements conducted in differing 
orientations. Visual assessment of LAA morphology displayed only fair agreement between read-
ers and would clearly benefit from the development of supporting quantitative tools or consensus 
readings between several specialists. 
Based on the measurements in the control population, a mid-diastolic LAA volume larger than 
5.6 mL/m2 is indicative of LAA enlargement. It was found that LAA was enlarged in more than half 
of patients with cryptogenic stroke/TIA. The assessment of LAA and LA volumes may be valuable 
in the etiological work-up of stroke/TIA without defined etiology.
In patients with stroke/TIA, LAA enlargement is poorly linked with causative stroke/TIA risk 
factors and other imaging measurements, implying that it has a relatively independent pathogenic 
mechanism for cardioembolic stroke/TIA. Since PAF recorded with 24-hour Holter ambulatory 
ECG explained only 19% of LAA increase, it would be ideal to target more extensive ECG moni-
toring for those stroke/TIA patients who have large LAA volumes. If the association between an 
enlarged LAA and an increased risk for cardioembolic stroke recurrence can be verified in future 
studies, cCT imaging may help to identify those patients who would benefit from more compre-
hensive ECG monitoring.
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Stroke is the leading cause of long-
term disability and a major burden 
on health-care resources worldwide. 
Embolism of cardiac origin accounts 
for 15–30% of ischemic strokes. Most 
cardiac thrombi originate from the 
left atrial appendage. An enlarged left 
atrial appendage may predispose the 
individual to blood coagulation and 
increase the risk of embolic events. 
By using computed tomography the 
left atrial appendage was found to be 
enlarged in more than half of patients 
with cryptogenic stroke.
